<!DOCTYPE html><html lang="en-US"><head><title>Advancements in Cholangiocarcinoma Treatment</title><meta property="og:title" content="Advancements in Cholangiocarcinoma Treatment"><meta name="author" content="Hsieh-Ting Lin"><meta property="article:author" content="Hsieh-Ting Lin"><meta charset="UTF-8"><meta name="viewport" content="width=device-width,height=device-height,initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>@media screen{body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{appearance:none;background-color:initial;border:0;color:inherit;cursor:pointer;font-size:inherit;opacity:.8;outline:none;padding:0;transition:opacity .2s linear;-webkit-tap-highlight-color:transparent}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:disabled{cursor:not-allowed;opacity:.15!important}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover{opacity:1}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:active{opacity:.6}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:not(:disabled){transition:none}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-prev{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNNjggOTAgMjggNTBsNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-next{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJtMzIgOTAgNDAtNDAtNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen]{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNNDAgNzBIMjBWNTBtMjAgMEwyMCA3MG00MC00MGgyMHYyMG0tMjAgMCAyMC0yMCIgY2xhc3M9ImEiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen]{background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNMjAgNTBoMjB2MjBtLTIwIDAgMjAtMjBtNDAgMEg2MFYzMG0yMCAwTDYwIDUwIiBjbGFzcz0iYSIvPjwvc3ZnPg==")}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter]{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNODcuOCA0Ny41Qzg5IDUwIDg3LjcgNTIgODUgNTJIMzVhOC43IDguNyAwIDAgMS03LjItNC41bC0xNS42LTMxQzExIDE0IDEyLjIgMTIgMTUgMTJoNTBhOC44IDguOCAwIDAgMSA3LjIgNC41ek02MCA1MnYzNm0tMTAgMGgyME00NSA0MmgyMCIvPjwvc3ZnPg==") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-bigger{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODBNNTIgOTBWMTAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-smaller{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}}@keyframes __bespoke_marp_transition_reduced_outgoing__{0%{opacity:1}to{opacity:0}}@keyframes __bespoke_marp_transition_reduced_incoming__{0%{mix-blend-mode:plus-lighter;opacity:0}to{mix-blend-mode:plus-lighter;opacity:1}}.bespoke-marp-note,.bespoke-marp-osc,.bespoke-progress-parent{display:none;transition:none}@media screen{::view-transition-group(*){animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-timing-function:ease}::view-transition-new(*),::view-transition-old(*){animation-delay:0s;animation-direction:var(--marp-bespoke-transition-animation-direction,normal);animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-fill-mode:both;animation-name:var(--marp-bespoke-transition-animation-name,var(--marp-bespoke-transition-animation-name-fallback,__bespoke_marp_transition_no_animation__));mix-blend-mode:normal}::view-transition-old(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_outgoing__;animation-timing-function:ease}::view-transition-new(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_incoming__;animation-timing-function:ease}::view-transition-new(root),::view-transition-old(root){animation-timing-function:linear}::view-transition-new(__bespoke_marp_transition_osc__),::view-transition-old(__bespoke_marp_transition_osc__){animation-duration:0s!important;animation-name:__bespoke_marp_transition_osc__!important}::view-transition-new(__bespoke_marp_transition_osc__){opacity:0!important}.bespoke-marp-transition-warming-up::view-transition-group(*),.bespoke-marp-transition-warming-up::view-transition-new(*),.bespoke-marp-transition-warming-up::view-transition-old(*){animation-play-state:paused!important}body,html{height:100%;margin:0}body{background:#000;overflow:hidden}svg.bespoke-marp-slide{content-visibility:hidden;opacity:0;pointer-events:none;z-index:-1}svg.bespoke-marp-slide:not(.bespoke-marp-active) *{view-transition-name:none!important}svg.bespoke-marp-slide.bespoke-marp-active{content-visibility:visible;opacity:1;pointer-events:auto;z-index:0}svg.bespoke-marp-slide.bespoke-marp-active.bespoke-marp-active-ready *{animation-name:__bespoke_marp__!important}@supports not (content-visibility:hidden){svg.bespoke-marp-slide[data-bespoke-marp-load=hideable]{display:none}svg.bespoke-marp-slide[data-bespoke-marp-load=hideable].bespoke-marp-active{display:block}}}@media screen and (prefers-reduced-motion:reduce){svg.bespoke-marp-slide *{view-transition-name:none!important}}@media screen{[data-bespoke-marp-fragment=inactive]{visibility:hidden}body[data-bespoke-view=""] .bespoke-marp-parent,body[data-bespoke-view=next] .bespoke-marp-parent{inset:0;position:absolute}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc{background:#000000a6;border-radius:7px;bottom:50px;color:#fff;contain:paint;display:block;font-family:Helvetica,Arial,sans-serif;font-size:16px;left:50%;line-height:0;opacity:1;padding:12px;position:absolute;touch-action:manipulation;transform:translateX(-50%);transition:opacity .2s linear;-webkit-user-select:none;user-select:none;white-space:nowrap;will-change:transform;z-index:1;view-transition-name:__bespoke_marp_transition_osc__}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>*,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>*{margin-left:6px}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>:first-child,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>:first-child{margin-left:0}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span{opacity:.8}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page]{display:inline-block;min-width:140px;text-align:center}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev]{height:32px;line-height:32px;width:32px}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive{cursor:none}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc{opacity:0;pointer-events:none}body[data-bespoke-view=""] svg.bespoke-marp-slide,body[data-bespoke-view=next] svg.bespoke-marp-slide{height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent{background:#222;display:flex;height:5px;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent+.bespoke-marp-parent{top:5px}body[data-bespoke-view=""] .bespoke-progress-parent .bespoke-progress-bar{background:#0288d1;flex:0 0 0;transition:flex-basis .2s cubic-bezier(0,1,1,1)}body[data-bespoke-view=next]{background:#0000}body[data-bespoke-view=presenter]{background:#161616}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container{display:grid;font-family:Helvetica,Arial,sans-serif;grid-template:"current dragbar next" minmax(140px,1fr) "current dragbar note" 2fr "info    dragbar note" 3em;grid-template-columns:minmax(3px,var(--bespoke-marp-presenter-split-ratio,66%)) 0 minmax(3px,1fr);height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent{grid-area:current;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide{height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide.bespoke-marp-active{filter:drop-shadow(0 3px 10px rgba(0,0,0,.5))}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container{background:#0288d1;cursor:col-resize;grid-area:dragbar;margin-left:-3px;opacity:0;position:relative;transition:opacity .4s linear .1s;width:6px;z-index:10}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container:hover{opacity:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container.active{opacity:1;transition-delay:0s}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container{background:#222;cursor:pointer;display:none;grid-area:next;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container iframe.bespoke-marp-presenter-next{background:#0000;border:0;display:block;filter:drop-shadow(0 3px 10px rgba(0,0,0,.5));height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container{background:#222;color:#eee;grid-area:note;position:relative;z-index:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper{display:block;inset:0;position:absolute}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons{background:#000000a6;border-radius:4px;bottom:0;display:flex;gap:4px;margin:12px;opacity:0;padding:6px;pointer-events:none;position:absolute;right:0;transition:opacity .2s linear}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons:focus-within,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper:focus-within+.bespoke-marp-presenter-note-buttons,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container:hover .bespoke-marp-presenter-note-buttons{opacity:1;pointer-events:auto}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note{box-sizing:border-box;font-size:calc(1.1em*var(--bespoke-marp-note-font-scale, 1));height:calc(100% - 40px);margin:20px;overflow:auto;padding-right:3px;white-space:pre-wrap;width:calc(100% - 40px);word-wrap:break-word;scrollbar-color:#eeeeee80 #0000;scrollbar-width:thin}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar{width:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-track{background:#0000}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-thumb{background:#eeeeee80;border-radius:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note:empty{pointer-events:none}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:first-child{margin-top:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:last-child{margin-bottom:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container{align-items:center;box-sizing:border-box;color:#eee;display:flex;flex-wrap:nowrap;grid-area:info;justify-content:center;overflow:hidden;padding:0 10px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{box-sizing:border-box;display:block;padding:0 10px;white-space:nowrap;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page{order:2;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page .bespoke-marp-presenter-info-page-text{display:inline-block;min-width:120px;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time{color:#999;order:1;text-align:left}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{color:#999;order:3;text-align:right}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer:hover{cursor:pointer}}@media print{.bespoke-marp-presenter-info-container,.bespoke-marp-presenter-next-container,.bespoke-marp-presenter-note-container{display:none}}</style><style>@charset "UTF-8";@import url("https://unpkg.com/markdown-it-admon/styles/admonition.css");@import url("https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css");@import url("https://fonts.googleapis.com/css2?family=Overpass+Mono:wght@400;500;600;700&display=swap");@import url("https://cdn.jsdelivr.net/npm/bootstrap-icons@1.11.2/font/bootstrap-icons.min.css");@import url("https://fonts.googleapis.com/css2?family=JetBrains+Mono:wght@400;600;800&display=swap");@import url("https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=JetBrains+Mono:wght@400;600;800&display=swap");@import url("https://fonts.googleapis.com/css2?family=Lora:ital,wght@1,700&display=swap");@import url("https://unpkg.com/boxicons@2.1.4/css/boxicons.min.css");@import url("https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200");@import "components/_lists";div#\:\$p > svg > foreignObject > section{width:1280px;height:720px;box-sizing:border-box;overflow:hidden;position:relative;scroll-snap-align:center center;-webkit-text-size-adjust:100%;text-size-adjust:100%}div#\:\$p > svg > foreignObject > section::after{bottom:0;content:attr(data-marpit-pagination);padding:inherit;pointer-events:none;position:absolute;right:0}div#\:\$p > svg > foreignObject > section:not([data-marpit-pagination])::after{display:none}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1){font-size:2em;margin:0.67em 0}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls{will-change:transform}@page {size:1280px 720px;margin:0}@media print{html, body{background-color:#fff;margin:0;page-break-inside:avoid;break-inside:avoid-page}div#\:\$p > svg > foreignObject > section{page-break-before:always;break-before:page}div#\:\$p > svg > foreignObject > section, div#\:\$p > svg > foreignObject > section *{-webkit-print-color-adjust:exact!important;animation-delay:0s!important;animation-duration:0s!important;color-adjust:exact!important;transition:none!important}div#\:\$p > svg[data-marpit-svg]{display:block;height:100vh;width:100vw}}div#\:\$p > svg > foreignObject > :where(section):not([\20 root]){--JAMA-foreground: #333;--JAMA-current-line: #e5e5e5;--JAMA-background: #ffffff;--JAMA-comment: #6272a4;--JAMA-cyan: #192b2f;--JAMA-blue: #2d696a;--JAMA-green: #6c9a77;--JAMA-orange: #ffb703;--JAMA-pink: #9a2f6b;--JAMA-purple: #4f2d7d;--JAMA-red: #d71635;--JAMA-yellow: #8c9434;--box-shadow: 0 10px 14px rgba(0, 0, 0, 0.2);--box-padding: 20px;}div#\:\$p > svg > foreignObject > section{font-size:22px;font-weight:500;font-family:"Inter", sans-serif;line-height:1.15;padding:35px 35px;color:var(--JAMA-foreground);background-color:var(--JAMA-background);border-bottom:10px solid;border-image:linear-gradient(to bottom, #6c9a77, #2d696a);border-image-slice:1}div#\:\$p > svg > foreignObject > section{--marpit-root-font-size: 22px;}div#\:\$p > svg > foreignObject > section ul{line-height:1.5}div#\:\$p > svg > foreignObject > section ul strong, div#\:\$p > svg > foreignObject > section table strong, div#\:\$p > svg > foreignObject > section p strong{padding:0px 2px 0px 2px;background:-webkit-linear-gradient(right, #6c9a77, #2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p > svg > foreignObject > section .large-title{font-size:4em!important}div#\:\$p > svg > foreignObject > section section.large-title{--marpit-root-font-size: 4em !important;}div#\:\$p > svg > foreignObject > section br{break-before:column}div#\:\$p > svg > foreignObject > section.lg table, div#\:\$p > svg > foreignObject > section.lg > ul{font-size:1.5em!important;line-height:1.4}div#\:\$p > svg > foreignObject > section.xl table{font-size:1.8em!important}div#\:\$p > svg > foreignObject > section p{font-size:1em;margin:1em 0 1em 0}div#\:\$p > svg > foreignObject > section mark{font-size:120%;font-weight:700;color:var(--JAMA-blue);display:inline-block;background:transparent;background:#e0e0e0;border-radius:10px;padding:5px 10px;margin:2px 0;padding-bottom:3px;background-position:0 100%;background-repeat:no-repeat;background-size:100% 5px}div#\:\$p > svg > foreignObject > section ins::before{content:"[ ";font-size:1.2em;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section ins::after{content:" ]";font-size:1.2em;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section ins{font-size:1em;color:var(--JAMA-blue);text-decoration:none}div#\:\$p > svg > foreignObject > section.scroll > ul{overflow-x:hidden;overflow-y:auto}div#\:\$p > svg > foreignObject > section .outline li{font-size:1.2em;font-weight:700;color:#dddddd}div#\:\$p > svg > foreignObject > section .outline strong{font-size:1em}div#\:\$p > svg > foreignObject > section > *:first-child, div#\:\$p > svg > foreignObject > section > header:first-child + *{margin-top:0}div#\:\$p > svg > foreignObject > section code{border-radius:0.2em;border:1px solid var(--JAMA-blue);color:var(--JAMA-blue);display:inline-block;font-family:"Open Sans", sans-serif;font-weight:700;letter-spacing:0.5;margin:0.1em;padding:0.1em 0.3em 0.1em 0.3em;vertical-align:baseline;animation-name:fadeIn;animation-duration:0.3s;animation-fill-mode:both;animation-delay:0.2s}div#\:\$p > svg > foreignObject > section > p{transition:transform 0.2s ease}div#\:\$p > svg > foreignObject > section a{text-decoration:none;font-weight:700;background:-webkit-linear-gradient(right, #6c9a77, #2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent;text-decoration:none}div#\:\$p > svg > foreignObject > section a::after{content:" ðŸ”—"}div#\:\$p > svg > foreignObject > section > a:hover{background:#2d696a}div#\:\$p > svg > foreignObject > section em{font-family:"Lora", serif;font-weight:700;font-style:italic}div#\:\$p > svg > foreignObject > section.blue::after, div#\:\$p > svg > foreignObject > section footer, div#\:\$p > svg > foreignObject > section::after{box-sizing:border-box;line-height:30px;padding:10px 20px;position:absolute;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section::after{content:attr(data-marpit-pagination) " of " attr(data-marpit-pagination-total)}div#\:\$p > svg > foreignObject > section header{position:absolute;box-sizing:border-box;background-color:var(--JAMA-blue);font-weight:500;color:var(--JAMA-background)!important;border-bottom-left-radius:15px;border-top-left-radius:15px;font-size:18px;height:30px;padding:5px 20px;right:0;top:8;font-weight:400;text-align:right}div#\:\$p > svg > foreignObject > section header a{background:var(--JAMA-background);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p > svg > foreignObject > section footer a:hover{background:var(--JAMA-blue);-webkit-background-clip:text;-webkit-text-fill-color:transparent;visibility:visible;opacity:1}div#\:\$p > svg > foreignObject > section footer a{text-decoration:none;opacity:0;transition:opacity 0.3s ease, visibility 0.3s ease}div#\:\$p > svg > foreignObject > section footer{left:0;right:0;bottom:0;font-size:14px}div#\:\$p > svg > foreignObject > section header strong{padding:0px 4px 0px 4px;font-weight:500;color:var(--JAMA-background)}div#\:\$p > svg > foreignObject > section.noheader header{display:none}div#\:\$p > svg > foreignObject > section.medium{font-size:36px}div#\:\$p > svg > foreignObject > section.medium{--marpit-root-font-size: 36px;}div#\:\$p > svg > foreignObject > section.large{font-size:48px}div#\:\$p > svg > foreignObject > section.large{--marpit-root-font-size: 48px;}div#\:\$p > svg > foreignObject > section.small{font-size:18px}div#\:\$p > svg > foreignObject > section.small{--marpit-root-font-size: 18px;}div#\:\$p > svg > foreignObject > section.happy{font-size:18px}div#\:\$p > svg > foreignObject > section.happy{--marpit-root-font-size: 18px;}div#\:\$p > svg > foreignObject > section.two{column-count:2;column-gap:1em;padding:10px}div#\:\$p > svg > foreignObject > section.center :is(h5, marp-h5), div#\:\$p > svg > foreignObject > section.center :is(h4, marp-h4), div#\:\$p > svg > foreignObject > section.center :is(h3, marp-h3), div#\:\$p > svg > foreignObject > section.center :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section.center :is(h1, marp-h1){text-align:center;justify-content:center!important;max-width:100%}div#\:\$p > svg > foreignObject > section.three{column-count:3}div#\:\$p > svg > foreignObject > section.four{column-count:4}div#\:\$p > svg > foreignObject > section::after{right:0;bottom:0;font-size:14px}div#\:\$p > svg > foreignObject > section::after{--marpit-root-font-size: 14px;}div#\:\$p > svg > foreignObject > section.free{display:flex;width:100%;gap:1em}div#\:\$p > svg > foreignObject > section.free div{display:flex;flex-direction:column}div#\:\$p > svg > foreignObject > section .cc{height:40px;left:40px;bottom:80px;position:absolute}div#\:\$p > svg > foreignObject > section .popup{position:fixed;top:20px;right:20px;background-color:#323232;color:#fff;padding:12px 20px;border-radius:4px;font-size:14px;box-shadow:0px 4px 6px rgba(0, 0, 0, 0.3);opacity:0;transform:translateY(-20px);transition:opacity 0.3s ease, transform 0.3s ease;z-index:1000}div#\:\$p > svg > foreignObject > section section.popup{--marpit-root-font-size: 14px;}div#\:\$p > svg > foreignObject > section .popup.show{opacity:1;transform:translateY(0)}div#\:\$p > svg > foreignObject > section .overlay{position:absolute;top:0;left:0;width:100%;height:100%;background-image:radial-gradient(#000 1px, transparent 1px);background-size:10px 10px;pointer-events:none}div#\:\$p > svg > foreignObject > section .diagram{padding:30px}div#\:\$p > svg > foreignObject > section .TD .level-1{display:flex;justify-content:center;gap:30px}div#\:\$p > svg > foreignObject > section .TD > .branch{display:flex;flex-direction:column;align-items:center}div#\:\$p > svg > foreignObject > section .TD > .node-group{display:flex;flex-direction:column;align-items:center;position:relative}div#\:\$p > svg > foreignObject > section .node{border:2px solid var(--JAMA-blue);padding:10px 20px;text-align:center;align-items:center;display:flex;justify-content:center;z-index:9}div#\:\$p > svg > foreignObject > section .TD .node{max-height:60px}div#\:\$p > svg > foreignObject > section .node > strong{white-space:nowrap}div#\:\$p > svg > foreignObject > section .branch > .node-group > .node{color:var(--JAMA-background);background:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section .TD .children{display:flex;gap:30px;margin-top:23px}div#\:\$p > svg > foreignObject > section .TD .node-group > .node{width:calc(100% - 44px);min-width:max-content;z-index:1}div#\:\$p > svg > foreignObject > section .TD .node-group .node:not(.level-1 > .branch > .node-group > .node){position:relative}div#\:\$p > svg > foreignObject > section .TD .node-group .node:not(.level-1 > .branch > .node-group > .node)::before{content:"";position:absolute;top:-25px;left:50%;width:1px;height:22px;background:#95a5a6;z-index:0}div#\:\$p > svg > foreignObject > section .TD .node-group .node:not(.level-1 > .branch > .node-group > .node)::after{content:"";position:absolute;top:-11px;left:50.5%;transform:translateX(-50%);width:0;height:0;border-left:4px solid transparent;border-right:4px solid transparent;border-top:10px solid #95a5a6}div#\:\$p > svg > foreignObject > section .LR .level-1{display:flex;flex-direction:column;gap:50px}div#\:\$p > svg > foreignObject > section .LR .branch{display:flex}div#\:\$p > svg > foreignObject > section .LR .node{position:relative}div#\:\$p > svg > foreignObject > section .LR .node-group{display:flex;position:relative}div#\:\$p > svg > foreignObject > section .LR .node-group > .node{height:auto;align-self:stretch}div#\:\$p > svg > foreignObject > section .LR .children{display:flex;flex-direction:column;gap:30px;margin-left:25px;padding:0 0 0 0}div#\:\$p > svg > foreignObject > section .LR .node-group:has(.children){align-items:stretch}div#\:\$p > svg > foreignObject > section .LR .node-group .children .node::before{content:"";position:absolute;top:50%;left:-27px;width:25px;height:1px;background:#95a5a6}div#\:\$p > svg > foreignObject > section .LR .node-group .children .node::after{content:"";position:absolute;left:-11px;top:51%;transform:translateY(-50%);width:0;height:0;border-top:4px solid transparent;border-bottom:4px solid transparent;border-left:10px solid #95a5a6}div#\:\$p > svg > foreignObject > section.blue > :is(h1, marp-h1){font-size:0px;color:var(--JAMA-blue);position:absolute;top:20px;left:20px}div#\:\$p > svg > foreignObject > section.blue > :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section.blue > :is(h3, marp-h3), div#\:\$p > svg > foreignObject > section.blue > :is(h4, marp-h4), div#\:\$p > svg > foreignObject > section.blue > :is(h5, marp-h5), div#\:\$p > svg > foreignObject > section.blue > :is(h6, marp-h6), div#\:\$p > svg > foreignObject > section.blue > footer, div#\:\$p > svg > foreignObject > section.blue li, div#\:\$p > svg > foreignObject > section.blue li::marker, div#\:\$p > svg > foreignObject > section.blue::after{color:var(--JAMA-background)}div#\:\$p > svg > foreignObject > section.blue a{color:var(--JAMA-background);background:none;-webkit-background-clip:border-box;-webkit-text-fill-color:initial;text-decoration:none}div#\:\$p > svg > foreignObject > section.blue a::after{content:none}div#\:\$p > svg > foreignObject > section.blue ol.agenda{font-size:0.8em;position:relative;list-style-type:upper-roman;padding-left:3em;top:40%;left:50%;line-height:1.5em;transform:translate(-50%, -50%)}div#\:\$p > svg > foreignObject > section.blue li.before{opacity:0.1}div#\:\$p > svg > foreignObject > section.blue li.current{font-weight:700;position:relative}div#\:\$p > svg > foreignObject > section.blue li.after{opacity:0.2}div#\:\$p > svg > foreignObject > section.blue li.after::marker{opacity:1!important}div#\:\$p > svg > foreignObject > section.blue{background:linear-gradient(50deg, var(--JAMA-blue) 20%, #6c9a77 100%);font-size:36px}div#\:\$p > svg > foreignObject > section.blue{--marpit-root-font-size: 36px;}div#\:\$p > svg > foreignObject > section.blue header{display:none}div#\:\$p > svg > foreignObject > section.blue footer.title_as_footer{left:60px}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1):first-of-type{padding-bottom:50px}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1){font-size:3em;font-weight:900;margin-bottom:20px;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section :is(h2, marp-h2){font-size:1.8em;font-weight:900;color:var(--JAMA-foreground);column-span:all}div#\:\$p > svg > foreignObject > section :is(h3, marp-h3){font-size:1.5em;font-weight:700;color:var(--JAMA-blue);column-span:all;padding-top:5px;padding-bottom:0.5em}div#\:\$p > svg > foreignObject > section :is(h4, marp-h4){font-weight:500;break-before:column;font-size:1.2em;color:var(--JAMA-blue);padding-top:25px}div#\:\$p > svg > foreignObject > section :is(h4, marp-h4).datetime{font-size:14px;position:absolute;text-align:center;bottom:18px;left:70px}div#\:\$p > svg > foreignObject > section :is(h5, marp-h5){font-size:1.2em;color:var(--JAMA-foreground)}div#\:\$p > svg > foreignObject > section :is(h6, marp-h6){font-size:1em;font-style:italic;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section :is(h3, marp-h3), div#\:\$p > svg > foreignObject > section :is(h4, marp-h4), div#\:\$p > svg > foreignObject > section :is(h5, marp-h5), div#\:\$p > svg > foreignObject > section :is(h6, marp-h6){margin:0.2em 0 0 0;max-width:90%}div#\:\$p > svg > foreignObject > section :is(h1, marp-h1) strong, div#\:\$p > svg > foreignObject > section :is(h2, marp-h2) strong, div#\:\$p > svg > foreignObject > section :is(h3, marp-h3) strong, div#\:\$p > svg > foreignObject > section :is(h4, marp-h4) strong, div#\:\$p > svg > foreignObject > section :is(h5, marp-h5) strong, div#\:\$p > svg > foreignObject > section :is(h6, marp-h6) strong{font-weight:inherit;background:-webkit-linear-gradient(right, #6c9a77, #2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p > svg > foreignObject > section .h2text, div#\:\$p > svg > foreignObject > section .bread{display:inline-block}div#\:\$p > svg > foreignObject > section .h2text{color:gray;padding-right:20px;font-size:0.8em}div#\:\$p > svg > foreignObject > section section.h2text{--marpit-root-font-size: 0.8em;}div#\:\$p > svg > foreignObject > section .firsth3afterh2{}@keyframes h2ToAnnotation{from{font-size:1.8em;font-weight:900;color:var(--JAMA-foreground);column-span:all;top:45px}to{color:gray;padding-right:20px;font-size:0.8em;position:absolute;top:30px}}div#\:\$p > svg > foreignObject > section.blue .menubar{display:none}div#\:\$p > svg > foreignObject > section .menubar{position:fixed;top:0;left:0;right:0;background:#fff;border-bottom:0.1px solid var(--JAMA-blue);z-index:1000;display:flex;justify-content:center}div#\:\$p > svg > foreignObject > section .menu{display:flex;gap:1em;margin:0;padding:0}div#\:\$p > svg > foreignObject > section .menu li{padding:0.2em;font-size:0.5em;color:#999!important;list-style:none}div#\:\$p > svg > foreignObject > section .menu li a{text-decoration:none;background:none;-webkit-background-clip:border-box;-webkit-text-fill-color:initial;text-decoration:none}div#\:\$p > svg > foreignObject > section .menu a::after{content:none}div#\:\$p > svg > foreignObject > section .menu li.done a{color:#999}div#\:\$p > svg > foreignObject > section .menu li.active a{font-weight:bold;padding:0px 10px;color:var(--JAMA-background)!important}div#\:\$p > svg > foreignObject > section .menu li.active{background-color:var(--JAMA-blue);font-weight:500;color:var(--JAMA-background)!important;list-style-position:inside;clip-path:polygon(0% 0%, 97% 0%, 100% 50%, 97% 100%, 0% 100%, 3% 50%)}div#\:\$p > svg > foreignObject > section .menu li.notyet a{color:#999}div#\:\$p > svg > foreignObject > section table{border-spacing:0;border-collapse:collapse;border-radius:2px;overflow:visible;margin:0;transition:transform 0.3s ease;margin:0 auto;z-index:1}div#\:\$p > svg > foreignObject > section table th, div#\:\$p > svg > foreignObject > section table td{font-size:0.8em;padding:0.4em 0.4em;border:1px solid var(--JAMA-background)}div#\:\$p > svg > foreignObject > section table th:last-child, div#\:\$p > svg > foreignObject > section table td:last-child{border-right:none}div#\:\$p > svg > foreignObject > section table thead th{background:var(--JAMA-blue);color:var(--JAMA-background);font-size:0.8em}div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(even) td, div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(even) th{background:var(--JAMA-current-line)}div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(odd) td, div#\:\$p > svg > foreignObject > section table tbody > tr:nth-child(odd) th{background:var(--JAMA-background)}div#\:\$p > svg > foreignObject > section tr.emphasize, div#\:\$p > svg > foreignObject > section tr:hover{transform:scale(1.02);position:relative;z-index:10;outline:2px solid var(--JAMA-blue);outline-offset:-2px}div#\:\$p > svg > foreignObject > section tr.emphasize::after, div#\:\$p > svg > foreignObject > section tr:hover::after{content:"";position:absolute;bottom:-15px;left:5%;width:90%;height:10px;background:rgba(0, 0, 0, 0.2);filter:blur(9px);z-index:-1;pointer-events:none}div#\:\$p > svg > foreignObject > section tr{transition:all 0.3s ease;transform-origin:center}div#\:\$p > svg > foreignObject > section td:hover{color:#2d696a;transition:opacity 0.5s ease}div#\:\$p > svg > foreignObject > section .responsive-table tr:hover{transform:scale(1.02);background:#f9f9f9;box-shadow:0 4px 15px rgba(0, 0, 0, 0.1);position:relative;z-index:1}div#\:\$p > svg > foreignObject > section .responsive-table{width:100%;margin:20px 0;border-collapse:collapse;background:white;box-shadow:0 1px 3px rgba(0, 0, 0, 0.1)}div#\:\$p > svg > foreignObject > section .responsive-table th{background:#f5f5f5;padding:12px;text-align:left;font-weight:bold;color:#333;border-bottom:2px solid #ddd}div#\:\$p > svg > foreignObject > section .responsive-table td{padding:12px;border-bottom:1px solid #eee}div#\:\$p > svg > foreignObject > section .responsive-table tr:hover{background:#f9f9f9}@media screen and (max-width: 600px){div#\:\$p > svg > foreignObject > section .responsive-table{display:block;overflow-x:auto}}div#\:\$p > svg > foreignObject > section .url-card{border:1px solid #e5e7eb;border-radius:calc(var(--marpit-root-font-size, 1rem) * 0.375);overflow:hidden;background-color:white;box-shadow:0 1px 3px 0 rgb(0 0 0 / 0.1);margin:calc(var(--marpit-root-font-size, 1rem) * 0.75) 0;transition:box-shadow 0.2s ease-in-out;max-width:600px}div#\:\$p > svg > foreignObject > section .url-card:hover{box-shadow:0 4px 6px -1px rgb(0 0 0 / 0.1), 0 2px 4px -5px rgb(0 0 0 / 0.1)}div#\:\$p > svg > foreignObject > section .url-card-container{display:flex;min-height:90px}div#\:\$p > svg > foreignObject > section .url-card-image{width:45%;background-color:#f9fafb;position:relative;overflow:hidden}div#\:\$p > svg > foreignObject > section .url-card-image img{position:absolute;top:0;left:0;width:100%;height:100%;object-fit:cover}div#\:\$p > svg > foreignObject > section .url-card-content{width:55%;padding:calc(var(--marpit-root-font-size, 1rem) * 0.6);display:flex;flex-direction:column}div#\:\$p > svg > foreignObject > section .url-card-title{font-size:calc(var(--marpit-root-font-size, 1rem) * 1);font-weight:600;margin-bottom:calc(var(--marpit-root-font-size, 1rem) * 0.375);color:#111827;display:-webkit-box;-webkit-line-clamp:2;-webkit-box-orient:vertical;overflow:hidden}div#\:\$p > svg > foreignObject > section section.url-card-title{--marpit-root-font-size: calc(var(--marpit-root-font-size, 1rem) * 1);}div#\:\$p > svg > foreignObject > section .url-card-description{font-size:calc(var(--marpit-root-font-size, 1rem) * 0.875);color:#4b5563;margin-bottom:calc(var(--marpit-root-font-size, 1rem) * 0.375);flex-grow:1;display:-webkit-box;-webkit-line-clamp:2;-webkit-box-orient:vertical;overflow:hidden}div#\:\$p > svg > foreignObject > section section.url-card-description{--marpit-root-font-size: calc(var(--marpit-root-font-size, 1rem) * 0.875);}div#\:\$p > svg > foreignObject > section .url-card-url{color:#6b7280;font-size:calc(var(--marpit-root-font-size, 1rem) * 0.75);margin-top:auto;display:-webkit-box;-webkit-line-clamp:1;-webkit-box-orient:vertical;overflow:hidden}div#\:\$p > svg > foreignObject > section section.url-card-url{--marpit-root-font-size: calc(var(--marpit-root-font-size, 1rem) * 0.75);}div#\:\$p > svg > foreignObject > section a.url-card{background:none;-webkit-background-clip:unset;-webkit-text-fill-color:initial;font-weight:normal;text-decoration:none;display:block}div#\:\$p > svg > foreignObject > section a.url-card::after{content:none}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre){display:block;min-height:1em;overflow:visible;margin:0;padding:0;position:relative;border-radius:0.5em}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code{box-sizing:border-box;line-height:1.5;background:#282a36;margin:0;min-width:100%;padding:1.2em;font-size:0.95em;color:#f8f8f2;overflow-x:auto;position:relative;display:block;font-family:"JetBrains Mono", "Fira Code", monospace;border-radius:0.5em;transition:all 0.3s ease}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code svg[data-marp-fitting="svg"]{max-height:calc(480px - 1.2em)}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code[class*="language-"]::before{position:absolute;top:0.5em;right:0.5em;padding:0.2em 0.6em;font-size:0.7em;background:#44475a;color:#f8f8f2;border-radius:0.3em;font-family:"JetBrains Mono", monospace;z-index:10;opacity:0.9;transition:opacity 0.2s ease}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre):hover code[class*="language-"]::before{opacity:1}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-javascript::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-js::before{content:"JavaScript"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-typescript::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-ts::before{content:"TypeScript"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-python::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-py::before{content:"Python"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-java::before{content:"Java"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-cpp::before{content:"C++"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-c::before{content:"C"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-css::before{content:"CSS"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-html::before{content:"HTML"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-xml::before{content:"XML"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-bash::before{content:"Bash"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-sh::before{content:"Shell"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-json::before{content:"JSON"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-yaml::before{content:"YAML"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-markdown::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-md::before{content:"Markdown"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-sql::before{content:"SQL"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-rust::before{content:"Rust"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-go::before{content:"Go"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-ruby::before, div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-rb::before{content:"Ruby"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-php::before{content:"PHP"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-r::before{content:"R"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-swift::before{content:"Swift"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-kotlin::before{content:"Kotlin"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-scala::before{content:"Scala"}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) code.language-dart::before{content:"Dart"}div#\:\$p > svg > foreignObject > section .hljs-built_in, div#\:\$p > svg > foreignObject > section .hljs-selector-tag, div#\:\$p > svg > foreignObject > section .hljs-section, div#\:\$p > svg > foreignObject > section .hljs-link{color:#8be9fd;font-style:italic}div#\:\$p > svg > foreignObject > section .hljs-keyword{color:#ff79c6;font-weight:bold}div#\:\$p > svg > foreignObject > section .hljs-title, div#\:\$p > svg > foreignObject > section .hljs-attr, div#\:\$p > svg > foreignObject > section .hljs-meta-keyword{color:#50fa7b}div#\:\$p > svg > foreignObject > section .hljs-string, div#\:\$p > svg > foreignObject > section .hljs-meta, div#\:\$p > svg > foreignObject > section .hljs-name, div#\:\$p > svg > foreignObject > section .hljs-type, div#\:\$p > svg > foreignObject > section .hljs-symbol, div#\:\$p > svg > foreignObject > section .hljs-bullet, div#\:\$p > svg > foreignObject > section .hljs-addition, div#\:\$p > svg > foreignObject > section .hljs-variable, div#\:\$p > svg > foreignObject > section .hljs-template-tag, div#\:\$p > svg > foreignObject > section .hljs-template-variable{color:#f1fa8c}div#\:\$p > svg > foreignObject > section .hljs-comment, div#\:\$p > svg > foreignObject > section .hljs-quote, div#\:\$p > svg > foreignObject > section .hljs-deletion{color:#6272a4;font-style:italic}div#\:\$p > svg > foreignObject > section .hljs-literal, div#\:\$p > svg > foreignObject > section .hljs-number{color:#bd93f9}div#\:\$p > svg > foreignObject > section .hljs-keyword, div#\:\$p > svg > foreignObject > section .hljs-selector-tag, div#\:\$p > svg > foreignObject > section .hljs-literal, div#\:\$p > svg > foreignObject > section .hljs-title, div#\:\$p > svg > foreignObject > section .hljs-section, div#\:\$p > svg > foreignObject > section .hljs-doctag, div#\:\$p > svg > foreignObject > section .hljs-type, div#\:\$p > svg > foreignObject > section .hljs-name, div#\:\$p > svg > foreignObject > section .hljs-strong{font-weight:bold}div#\:\$p > svg > foreignObject > section .hljs-emphasis{font-style:italic}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol{all:unset;display:grid;grid-template-columns:auto 1fr;counter-reset:line-number 0;padding-right:1em}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li{display:contents;color:#f8f8f2;font-weight:400;line-height:1.5;font-family:"JetBrains Mono", monospace}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li > :is(span, marp-span){padding:0 0.5em;transition:all 0.2s ease;position:relative}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li > :is(span, marp-span):hover{font-weight:600;color:#ffb703}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li > :is(span, marp-span):hover::after{content:"";position:absolute;left:0;top:0;width:100%;height:100%;background:rgba(255, 255, 255, 0.1);border-radius:0.2em;pointer-events:none}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li :is(span, marp-span)[data-marp-line-number]::before{display:block;content:counter(line-number);counter-increment:line-number;text-align:right;color:#6272a4;font-weight:500;background:#2c2e3a;border-right:3px solid #44475a;margin-right:0.8em;padding:0 0.6em;transition:all 0.2s ease}div#\:\$p > svg > foreignObject > section :is(pre, marp-pre) ol li:hover :is(span, marp-span)[data-marp-line-number]::before{color:#8be9fd;border-right-color:#6272a4}@keyframes fadeIn{from{opacity:0;transform:translateY(1em)}to{opacity:1;transform:translateY(0)}}div#\:\$p > svg > foreignObject > section blockquote{opacity:0.7;font-size:10px!important;margin:5px 0 0 0;padding-top:5px;border-top:0.1px solid var(--JAMA-blue);margin-top:10px;color:var(--JAMA-foreground);position:absolute;bottom:0px;right:90px;left:25px}div#\:\$p > svg > foreignObject > section blockquote::before{content:"";display:block;font-weight:bold;position:absolute;color:var(--JAMA-green);top:0;left:0}div#\:\$p > svg > foreignObject > section blockquote > *:first-child{margin-top:0}div#\:\$p > svg > foreignObject > section blockquote > blockquote > blockquote{font-size:50%;font-weight:400;padding:0;margin:0;border:0;border-top:0.1em dashed #555;position:absolute;bottom:-10px;left:10px}div#\:\$p > svg > foreignObject > section blockquote::before, div#\:\$p > svg > foreignObject > section blockquote::after{color:var(--JAMA-comment)}div#\:\$p > svg > foreignObject > section .blur-shadow{position:relative}div#\:\$p > svg > foreignObject > section .blur-shadow::after{content:"";position:absolute;bottom:var(--blur-bottom, -4px);left:0;width:100%;height:var(--blur-height, 8px);background:var(--blur-color, rgba(0, 0, 0, 0.2));filter:blur(var(--blur-radius, 4px));z-index:-1;pointer-events:none}div#\:\$p > svg > foreignObject > section img.left{display:block;margin:0}div#\:\$p > svg > foreignObject > section img{display:inline-block;margin:0 auto}div#\:\$p > svg > foreignObject > section .outline li{font-size:1.2em;font-weight:700;color:#dddddd}div#\:\$p > svg > foreignObject > section .outline strong{font-size:1em}div#\:\$p > svg > foreignObject > section .free{display:flex;width:100%;gap:1em}div#\:\$p > svg > foreignObject > section .free div{display:flex;flex-direction:column;justify-content:center}div#\:\$p > svg > foreignObject > section .free > div img:not(.emoji){width:auto;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .free > div img:not(.emoji){width:auto;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .bigtable > div{justify-content:center;display:flex;flex-direction:column}div#\:\$p > svg > foreignObject > section .bigtable > div > table{border-spacing:0;border-collapse:collapse;border-radius:9px;overflow:hidden;margin:1em 0 0 0;border:1px solid var(--JAMA-background)}div#\:\$p > svg > foreignObject > section .bigtable > div > table th, div#\:\$p > svg > foreignObject > section .bigtable > div > table td{text-align:center;font-size:1.8em;padding:0.4em 1.4em;border-left:50px solid var(--JAMA-background);border-right:50px solid var(--JAMA-background);background:#eeeeee}div#\:\$p > svg > foreignObject > section .bigtable > div > table thead th{text-align:center;background:var(--JAMA-blue);color:var(--JAMA-background);border-top:5px solid var(--JAMA-background);font-size:1.8em;color:white}div#\:\$p > svg > foreignObject > section .bigtable > div > table tbody > tr:nth-child(even) td, div#\:\$p > svg > foreignObject > section .bigtable > div > table tbody > tr:nth-child(even) th{background:var(--JAMA-current-line);font-size:1.8em}div#\:\$p > svg > foreignObject > section .even{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1.5);justify-content:space-between}div#\:\$p > svg > foreignObject > section .even > div img{width:calc(var(--marpit-root-font-size, 1rem) * 5.1)}div#\:\$p > svg > foreignObject > section .even div{display:flex;flex-direction:column;flex-grow:1;padding:15px;margin:10px 0}div#\:\$p > svg > foreignObject > section even :is(h2, marp-h2){display:flex;flex-direction:column;flex-grow:1;padding:15px;margin:10px 0}div#\:\$p > svg > foreignObject > section .boxlist{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1.5);justify-content:space-between}div#\:\$p > svg > foreignObject > section .boxlist div{display:flex;flex-direction:column;justify-content:center;flex-grow:1;background-color:#efefef;border-bottom:10px solid var(--JAMA-blue);padding:15px;margin:20px 20px}div#\:\$p > svg > foreignObject > section .boxlist ul{display:flex;flex-wrap:wrap;padding:0;margin:0}div#\:\$p > svg > foreignObject > section .boxlist ul li{display:inline-flex;margin-right:20px;list-style-type:none}div#\:\$p > svg > foreignObject > section .boxlist ul li::before{content:"â— ";margin-right:8px}div#\:\$p > svg > foreignObject > section .top{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1.5)}div#\:\$p > svg > foreignObject > section .top div{justify-content:center}div#\:\$p > svg > foreignObject > section .container{display:flex}div#\:\$p > svg > foreignObject > section .tri{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .tri > div{flex:1;width:calc(33% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding:var(--box-padding);background-color:#efefef;border-bottom:10px solid var(--JAMA-blue);transition:transform 0.3s ease;margin:20px 0px}div#\:\$p > svg > foreignObject > section .tri > div > p > strong{font-size:1.5em;font-weight:900;color:var(--JAMA-blue);column-span:all}div#\:\$p > svg > foreignObject > section .tetra{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .tetra > div{flex:1;width:calc(25% - calc(var(--marpit-root-font-size, 1rem) * 0.5));border-bottom:10px solid var(--JAMA-blue);background-color:#efefef;padding:var(--box-padding);margin:20px 0px;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .third{display:flex;align-items:left;justify-content:space-between}div#\:\$p > svg > foreignObject > section .third > div{flex:1;padding-right:0.5em;box-sizing:border-box}div#\:\$p > svg > foreignObject > section .third img{max-width:340px!important;width:100%;height:auto}div#\:\$p > svg > foreignObject > section .twoone{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .twoone > div:first-child{flex:2;width:calc(66% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .twoone > div:last-child{flex:1;width:calc(33% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .onetwo{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .onetwo > div:first-child{flex:1;width:calc(33% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .onetwo > div:last-child{flex:2;width:calc(66% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .half{display:flex;justify-content:center;align-items:center;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .half > div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5));padding-right:1em;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section .half > div:hover, div#\:\$p > svg > foreignObject > section .free > div img:hover{transform:translateY(-10px);transform-origin:center;border-top-width:0px}div#\:\$p > svg > foreignObject > section .columns{padding-top:1em;padding-right:1em;display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p > svg > foreignObject > section .columns > div img:not(.emoji){display:block;margin:0 auto;max-width:100%;height:auto}div#\:\$p > svg > foreignObject > section .columns > div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5));transition:transform 0.3s ease;padding-right:0.5em}div#\:\$p > svg > foreignObject > section .columns div:not(:last-child){position:relative}div#\:\$p > svg > foreignObject > section .columns div:not(:last-child)::after{content:"";position:absolute;right:0;top:30px;bottom:30px;border-right:1px dashed #2d696a;width:0}div#\:\$p > svg > foreignObject > section .columns div:hover{transform:translateY(-5px);transform-origin:center;border-top-width:0px}div#\:\$p > svg > foreignObject > section hr{border:1px dashed var(--JAMA-blue);margin-top:10px;opacity:0.5;margin-bottom:10px}div#\:\$p > svg > foreignObject > section .dash{border:none;border-top:1px dashed #2d696a;height:0;margin:0.4em 0}div#\:\$p > svg > foreignObject > section.center{margin:0;max-width:100%!important;display:block;text-align:center;place-content:safe center center;padding:100px}div#\:\$p > svg > foreignObject > section.center{text-align:left}div#\:\$p > svg > foreignObject > section.center :is(h2, marp-h2), div#\:\$p > svg > foreignObject > section.center :is(h3, marp-h3){margin:1em!important;max-width:100%!important}div#\:\$p > svg > foreignObject > section a{color:var(--JAMA-cyan)}div#\:\$p > svg > foreignObject > section ul li:hover::marker{transform:scale(1.5);color:var(--JAMA-orange)}div#\:\$p > svg > foreignObject > section li{transition:opacity 0.3s ease;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section li::marker{color:#2d696a}div#\:\$p > svg > foreignObject > section li:hover{transition:transform 0.3s ease;text-decoration:underline;text-decoration-color:#6c9a77;text-decoration-style:solid;text-decoration-thickness:1px}div#\:\$p > svg > foreignObject > section .fa-solid{color:var(--JAMA-orange)}div#\:\$p > svg > foreignObject > section .scroll li:hover{transform:translateX(15px);transition:transform 0.2s ease;text-decoration:underline;text-decoration-color:#6c9a77;text-decoration-style:solid;text-decoration-thickness:5px}div#\:\$p > svg > foreignObject > section li[data-bespoke-marp-fragment="active"]{opacity:1;transition:transform 0.3s ease}div#\:\$p > svg > foreignObject > section li[data-bespoke-marp-fragment="inactive"]{transition:transform 0.3s ease;visibility:visible;opacity:0.2}div#\:\$p > svg > foreignObject > section button{display:inline-block;outline:none;cursor:pointer;font-size:inherit;line-height:1;border-radius:200px;transition-property:background-color, border-color, color, box-shadow, filter;transition-duration:0.3s;border:1px solid transparent;letter-spacing:2px;min-width:160px;text-transform:uppercase;white-space:normal;font-weight:700;text-align:center;padding:2px 2px;margin-left:20px;color:#fff;background-color:#2d696a;height:48px}div#\:\$p > svg > foreignObject > section button :hover{transform:scale(1.04);background-color:#2d696a}div#\:\$p > svg > foreignObject > section .container{border:1px solid black;margin:10px}div#\:\$p > svg > foreignObject > section details{display:inline-block;position:relative}div#\:\$p > svg > foreignObject > section details > *:not(summary){position:absolute;z-index:50;margin-top:8px;padding:30px;width:356px;background:white;border-radius:8px;box-shadow:0 10px 15px -3px rgba(0, 0, 0, 0.1), 0 4px 6px -2px rgba(0, 0, 0, 0.05);border:1px solid #e5e7eb;font-size:18px;color:#4b5563;animation:fadeIn 0.2s ease-out}div#\:\$p > svg > foreignObject > section details > div#\:\$p > svg > foreignObject > section section:not(summary){--marpit-root-font-size: 18px;}div#\:\$p > svg > foreignObject > section summary{cursor:pointer;padding:8px 16px;background:#f3f4f6;border-radius:20px;color:#4b5563;font-size:18px;font-weight:500;display:inline-flex;align-items:center;gap:8px;transition:background-color 0.2s ease;border:1px solid transparent}div#\:\$p > svg > foreignObject > section summary:hover{background:#e5e7eb}div#\:\$p > svg > foreignObject > section summary:focus{outline:none;border-color:var(--JAMA-blue);box-shadow:0 0 0 3px rgba(147, 197, 253, 0.3)}@keyframes fadeIn{from{opacity:0;transform:translateY(-4px)}to{opacity:1;transform:translateY(0)}}div#\:\$p > svg > foreignObject > section svg.markmap{width:200%}div#\:\$p > svg > foreignObject > section div[class^="admonition"]{column-span:all;margin:0.8em 10px 0.8em}div#\:\$p > svg > foreignObject > section div[class^="admonition"] > p > strong{font-weight:bold}div#\:\$p > svg > foreignObject > section p.admonition-title{padding:5px 0px 5px 40px;margin:15px 0px 0px 0px}div#\:\$p > svg > foreignObject > section p.admonition-title::before{padding-left:10px;padding-top:4px}div#\:\$p > svg > foreignObject > section .table-of-contents{font-size:14px;columns:2;list-style-type:disc}div#\:\$p > svg > foreignObject > section section.table-of-contents{--marpit-root-font-size: 14px;}div#\:\$p > svg > foreignObject > section .box{width:40%;margin:0 auto;background:rgba(255, 255, 255, 0.2);padding:35px;border:2px solid #fff;border-radius:20px/50px;background-clip:padding-box;text-align:center}div#\:\$p > svg > foreignObject > section .button{font-size:1em;padding:2px;border:2px solid #06d85f;text-decoration:none;cursor:pointer;transition:all 0.3s ease-out}div#\:\$p > svg > foreignObject > section section.button{--marpit-root-font-size: 1em;}div#\:\$p > svg > foreignObject > section .button:hover{background:#06d85f}div#\:\$p > svg > foreignObject > section .overlay{position:fixed;top:0;bottom:0;left:0;right:0;background:rgba(0, 0, 0, 0.7);transition:opacity 500ms;visibility:hidden;opacity:0}div#\:\$p > svg > foreignObject > section .overlay:target{visibility:visible;opacity:1}div#\:\$p > svg > foreignObject > section .popup{margin:70px auto;padding:20px;background:#fff;border-radius:5px;width:70%;position:relative;transition:all 5s ease-in-out}div#\:\$p > svg > foreignObject > section .popup :is(h2, marp-h2){margin-top:0;color:#333}div#\:\$p > svg > foreignObject > section .popup .close{position:absolute;top:20px;right:30px;transition:all 200ms;font-size:30px;font-weight:bold;text-decoration:none;color:#333}div#\:\$p > svg > foreignObject > section .popup div#\:\$p > svg > foreignObject > section section.close{--marpit-root-font-size: 30px;}div#\:\$p > svg > foreignObject > section .popup .close:hover{color:#06d85f}div#\:\$p > svg > foreignObject > section .popup .content{max-height:30%;overflow:auto}div#\:\$p > svg > foreignObject > section img[alt*="circle"]{border-radius:50%}div#\:\$p > svg > foreignObject > section ruby rt{color:deeppink}@media screen and (max-width: 1000px){div#\:\$p > svg > foreignObject > section .box{width:70%}div#\:\$p > svg > foreignObject > section .popup{width:70%}}div#\:\$p > svg > foreignObject > section .markmap > svg{width:100%;height:550px;font:300 16px/20px sans-serif}div#\:\$p > svg > foreignObject > section .material-symbols-outlined{font-size:140px;color:#2d696a;margin-bottom:2px;font-variation-settings:"FILL" 1, "wght" 500, "GRAD" 100, "opsz" 48}div#\:\$p > svg > foreignObject > section section.material-symbols-outlined{--marpit-root-font-size: 140px;}div#\:\$p > svg > foreignObject > section .bx{color:#2d696a}div#\:\$p > svg > foreignObject > section g{font-size:60px}div#\:\$p > svg > foreignObject > section .mdi-label{padding:0.2em 0.6em 0.3em;font-size:75%;font-weight:700;white-space:nowrap;vertical-align:baseline;border-radius:0.25em}div#\:\$p > svg > foreignObject > section section.mdi-label{--marpit-root-font-size: 75%;}div#\:\$p > svg > foreignObject > section .mdi-label-text-light{color:white}div#\:\$p > svg > foreignObject > section .mdi-label-text-dark{color:#332900}div#\:\$p > svg > foreignObject > section .tag{border:2px solid var(--JAMA-blue);border-radius:10px;padding:5px 10px;display:inline-block;color:var(--JAMA-blue);font-weight:bold;transition:transform 0.2s ease, box-shadow 0.2s ease}div#\:\$p > svg > foreignObject > section .tag:hover{transform:translateY(-5px);box-shadow:0 4px 8px rgba(0, 0, 0, 0.2)}div#\:\$p > svg > foreignObject > section ::selection{background-color:var(--JAMA-blue);color:white!important}div#\:\$p > svg > foreignObject > section .lab ul ul{display:inline-block;margin-left:auto;padding-left:0;list-style-type:none}div#\:\$p > svg > foreignObject > section .lab ul ul li{margin-right:10px}div#\:\$p > svg > foreignObject > section .row{display:flex;min-height:30vh;max-height:80vh;margin:50;flex-wrap:wrap}div#\:\$p > svg > foreignObject > section .row > ul:not(ul ul){flex:1;margin-left:150}div#\:\$p > svg > foreignObject > section .row > ul > li{padding:10px;flex:1;min-height:30vh}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child ul{padding:20px;background:var(--JAMA-blue);min-height:20vh}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child ul{border-radius:1px}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child ul, div#\:\$p > svg > foreignObject > section .row > ul > li:first-child li{font-size:24px;color:var(--JAMA-background);line-height:initial;weight:initial;list-style:none}div#\:\$p > svg > foreignObject > section .row > ul > li:first-child{weight:900;line-height:2.5;text-align:center;list-style:none;font-size:1.5em!important;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section .c2, div#\:\$p > svg > foreignObject > section .c3, div#\:\$p > svg > foreignObject > section .c4{column-gap:20px;border-top:2px solid gray;padding-top:25px;margin-top:25px;min-height:60vh;column-fill:auto}div#\:\$p > svg > foreignObject > section .c2{column-count:2}div#\:\$p > svg > foreignObject > section .c3{column-count:3}div#\:\$p > svg > foreignObject > section .c4{column-count:4}div#\:\$p > svg > foreignObject > section.timeline > ul:first-of-type{display:flex;gap:10px;margin-top:255px;border-top:1px solid #999;margin:0}div#\:\$p > svg > foreignObject > section.timeline > ul:first-of-type code{border:2px solid var(--JAMA-blue)!important}div#\:\$p > svg > foreignObject > section.timeline > ul > li{padding-top:20px;border-left:1px dashed #999;padding-left:20px;list-style:none;break-before:column}div#\:\$p > svg > foreignObject > section.timeline :is(h2, marp-h2){padding-bottom:0.8em}div#\:\$p > svg > foreignObject > section.timeline mark{font-weight:500;font-size:1.2em;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section.flexList :is(h2, marp-h2){padding-bottom:1em}div#\:\$p > svg > foreignObject > section.flexImg > ul, div#\:\$p > svg > foreignObject > section.flexList > ul{display:flex;flex-direction:row;gap:20px;padding:0px;line-height:2.5em;justify-content:space-evenly;position:relative}div#\:\$p > svg > foreignObject > section.flexList > ul > li{flex-grow:1;break-before:column}div#\:\$p > svg > foreignObject > section.flexList mark{font-weight:500;font-size:1.2em;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section.flexImg > ul{list-style:none}div#\:\$p > svg > foreignObject > section.flexImg > ul > li img{max-width:100%;max-height:100%;object-fit:contain}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-volume-slider{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-mute-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-timeline{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-current-time-display{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-fullscreen-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-time-remaining-display{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-toggle-closed-captions-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-volume-slider{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-play-button{display:none}div#\:\$p > svg > foreignObject > section video::-webkit-media-controls-panel{background-image:none!important}div#\:\$p > svg > foreignObject > section .video-progress-container{width:100%;height:4px;background:rgba(255, 255, 255, 0.2);position:relative;overflow:hidden}div#\:\$p > svg > foreignObject > section .video-progress-bar{height:100%;background:#your-color-here;width:0;transition:width 0.2s ease}div#\:\$p > svg > foreignObject > section .markmap ul{padding-left:20px;position:relative;list-style-type:none}div#\:\$p > svg > foreignObject > section .markmap li{margin:0;padding:10px 5px;line-height:1.5;white-space:nowrap;position:relative}div#\:\$p > svg > foreignObject > section .markmap li::before, div#\:\$p > svg > foreignObject > section .markmap li::after{content:"";position:absolute;left:0}div#\:\$p > svg > foreignObject > section .markmap li::before{border-left:1px solid #000;top:0;bottom:50%;height:50%;width:20px}div#\:\$p > svg > foreignObject > section .markmap li::after{border-top:1px solid #000;top:50%;left:20px;width:calc(100% - 20px)}div#\:\$p > svg > foreignObject > section .markmap li > ul::before{content:"";position:absolute;top:0;left:0;border-left:1px solid #000;bottom:0;height:100%}div#\:\$p > svg > foreignObject > section .markmap ul ul{margin-left:20px;padding-left:0}div#\:\$p > svg > foreignObject > section .markmap li:first-child::before{height:50%}div#\:\$p > svg > foreignObject > section .markmap li:last-child::before{top:50%;height:50%}div#\:\$p > svg > foreignObject > section .markmap li:only-child::before{display:none}div#\:\$p > svg > foreignObject > section .markmap li:only-child::after{width:20px}div#\:\$p > svg > foreignObject > section .markmap ul ul::before{left:20px}div#\:\$p > svg > foreignObject > section .basic-label-container{fill:#f5f5f5;stroke:2px solid #333;padding:10px;border-radius:4px}div#\:\$p > svg > foreignObject > section.chat > ul{list-style:none;padding:0;margin:20px auto;max-width:600px;max-width:80%;margin-bottom:50px;display:flex;flex-direction:column;min-height:100px;justify-content:flex-end}div#\:\$p > svg > foreignObject > section.chat > ul::after{content:"Type a message...";display:block;padding:15px;padding-left:40px;background:white;border:1px solid #ddd;border-radius:35px;color:#999;margin-top:40px}div#\:\$p > svg > foreignObject > section.chat > ul li{margin:10px 0;padding:15px 20px;border-radius:25px;width:fit-content;max-width:80%}div#\:\$p > svg > foreignObject > section.chat > ul li:nth-child(even){background-color:var(--JAMA-background);margin-right:auto;margin-left:0;border-bottom-left-radius:5px;position:relative}div#\:\$p > svg > foreignObject > section.chat > ul li:nth-child(even)::before{content:"";position:absolute;left:-50px;top:50%;transform:translateY(-50%);width:40px;height:40px;border-radius:50%;background-image:url("lizard_realistic_small.jpg");background-size:cover;background-position:center;background-repeat:no-repeat}div#\:\$p > svg > foreignObject > section.chat > ul li:nth-child(odd){background-color:#e0e0e0;margin-left:auto;margin-right:0;text-align:left;border-bottom-right-radius:5px}div#\:\$p > svg > foreignObject > section.chat > ul li:hover{transform:scale(1.1);text-decoration:none}div#\:\$p > svg > foreignObject > section.chat > ul li[data-bespoke-marp-fragment="inactive"]{display:none}div#\:\$p > svg > foreignObject > section svg[data-marp-fitting="svg"]{max-height:580px}div#\:\$p > svg > foreignObject > section img[alt*="uml"]{max-height:450px;width:auto}div#\:\$p > svg > foreignObject > section img{max-width:1200px!important;max-height:520px!important;width:auto;height:auto;object-fit:contain}div#\:\$p > svg > foreignObject > section img[alt*="inline"]{display:inline}div#\:\$p > svg > foreignObject > section img[alt*="badge"]{height:30px}div#\:\$p > svg > foreignObject > section img[alt*="svg"]{height:30px;font-family:"Inter", sans-serif}div#\:\$p > svg > foreignObject > section img[alt*="emojik"]{animation:move 2.5s infinite cubic-bezier(0.6, 0.05, 0.4, 0.95)}div#\:\$p > svg > foreignObject > section img[alt*="RLQ"]{position:absolute;right:80px;bottom:80px;z-index:0}div#\:\$p > svg > foreignObject > section .webcam-container{position:absolute;right:80px;bottom:80px;display:flex;margin:10px auto;width:250px;height:250px;border:8px solid var(--JAMA-blue);border-radius:50%}div#\:\$p > svg > foreignObject > section .webcam-video{width:100%;height:100%;object-fit:cover;z-index:0;border-radius:inherit}div#\:\$p > svg > foreignObject > section img[alt*="RUQ"]{position:absolute;right:80px;top:80px}div#\:\$p > svg > foreignObject > section img{animation-name:fadeIn;animation-duration:0.2s;animation-fill-mode:both;animation-delay:0.3s}div#\:\$p > svg > foreignObject > section a.wikilink{display:inline;color:#0366d6;text-decoration:none;border-bottom:1px dashed #0366d6;padding-bottom:1px;transition:all 0.2s ease;opacity:1!important;visibility:visible!important}div#\:\$p > svg > foreignObject > section a.wikilink:hover{color:#0056b3;border-bottom:1px solid #0056b3;text-decoration:none}div#\:\$p > svg > foreignObject > section a.wikilink[href="#table-of-contents"]{color:inherit;border-bottom:1px dashed currentColor}div#\:\$p > svg > foreignObject > section li a.wikilink, div#\:\$p > svg > foreignObject > section td a.wikilink{margin:0 2px}div#\:\$p > svg > foreignObject > section code a.wikilink{border-bottom:none;padding-bottom:0}div#\:\$p > svg > foreignObject > section sup, div#\:\$p > svg > foreignObject > section sub{font-size:0.8em;color:var(--JAMA-blue)}div#\:\$p > svg > foreignObject > section kbd{background-color:#eee;border:0;border-radius:0.125em;box-shadow:+0.2em +0.125em 0.125em rgba(0, 0, 0, 0.25), 0 0 0 0.04em rgba(0, 0, 0, 0.3), 0.02em 0.02em 0.02em rgba(0, 0, 0, 0.4) inset, +0.05em +0.05em 0.02em rgba(255, 255, 255, 0.8) inset;color:var(--JAMA-foreground);display:inline-block;padding:0.2em 0.4em;margin:0 0.35em;font-family:"JetBrains Mono", monospace;font-size:1em;cursor:pointer;user-select:none;transition:all 0.2s ease}div#\:\$p > svg > foreignObject > section kbd:hover{background-color:#eee;border-radius:0.125em;background-color:#f3f3f3;box-shadow:0 4px 8px rgba(0, 0, 0, 0.2)}div#\:\$p > svg > foreignObject > section kbd:active{background-color:#e6e6e6;box-shadow:0.1em 0.1em 0.1em rgba(0, 0, 0, 0.2), 0 0 0 0.05em rgba(0, 0, 0, 0.4), -0.025em -0.05em 0.025em rgba(255, 255, 255, 0.8) inset;transform:translateY(5px)}div#\:\$p > svg > foreignObject > section .markdown-alert{display:flex;gap:calc(var(--marpit-root-font-size, 1rem) * 2);padding:0.5em;border-left:calc(var(--marpit-root-font-size, 1rem) * 0.2) solid;padding-bottom:0px;padding-top:0px;border-color:var(--border-color);background-color:#f1f1f1}div#\:\$p > svg > foreignObject > section .markdown-alert > p{line-height:1em}div#\:\$p > svg > foreignObject > section .markdown-alert > :is(span, marp-span){display:flex;flex-direction:row;align-items:center;color:var(--border-color)}div#\:\$p > svg > foreignObject > section .markdown-alert .markdown-alert-icon{margin-right:0.5em;fill:var(--border-color)}div#\:\$p > svg > foreignObject > section .markdown-alert.note{--border-color: #539bf5;}div#\:\$p > svg > foreignObject > section .markdown-alert.warning{--border-color: #c69026;}div#\:\$p > svg > foreignObject > section .markdown-alert.important{--border-color: #986ee2;}div#\:\$p > svg > foreignObject > section .markdown-alert.caution{--border-color: #e5534b;}div#\:\$p > svg > foreignObject > section .markdown-alert.tip{--border-color: #57ab5a;}div#\:\$p > svg > foreignObject > section .task-list-item-checkbox{transform:scale(1.5)}@keyframes weightChange{0%{font-variation-settings:"wght" 500;letter-spacing:1px}100%{font-variation-settings:"wght" 800;letter-spacing:10px}}div#\:\$p > svg > foreignObject > section .animated-text{font-variation-settings:"wght" 500;animation:weightChange 0.5s ease-in-out infinite alternate}@keyframes underline-animation{0%{color:var(--JAMA-foreground);background-size:0% 44px;background-position:0 100%}100%{color:var(--JAMA-background);background-size:110% 44px;background-position:0% 100%}}@keyframes pulse{0%{font-variation-settings:"wght" 200}50%{font-variation-settings:"wght" 500}100%{font-variation-settings:"wght" 200}}@keyframes head-fade-in{from{opacity:0;transform:translateY(-40px)}to{opacity:1;transform:translateY(0)}}@keyframes move{0%{transform:translateX(0)}50%{transform:translateX(-20px)}100%{transform:translateX(0)}}@keyframes slideInRight{from{transform:translateX(100%)}to{transform:translateX(0)}}@keyframes fadeIn{from{opacity:0}to{opacity:1}}@keyframes fade{0%{opacity:0}50%{opacity:1}100%{opacity:0}}@keyframes typewriter{from{width:0}to{width:100%}}@keyframes blinkTextCursor{from{border-right-color:rgba(0, 0, 0, 0.75)}to{border-right-color:transparent}}@keyframes bounceSize{0%, 100%{transform:scale(1);transform-origin:left center}50%{transform:scale(1.05)}}@keyframes underline-animation{0%{color:var(--JAMA-foreground);background-size:0% 44px;background-position:0 100%}100%{color:var(--JAMA-background);background-size:110% 44px;background-position:0% 100%}}div#\:\$p > svg > foreignObject > section ::view-transition-group(*){animation-duration:300ms}div#\:\$p > svg > foreignObject > section ::view-transition-old(*), div#\:\$p > svg > foreignObject > section ::view-transition-new(*){mix-blend-mode:normal}div#\:\$p > svg > foreignObject > section ::view-transition * svg, div#\:\$p > svg > foreignObject > section ::view-transition * foreignObject{transition:none;animation:none}div#\:\$p > svg > foreignObject > :where(section){container-type:size}div#\:\$p > svg > foreignObject > section img[data-marp-twemoji]{background:transparent;height:1em;margin:0 .05em 0 .1em;vertical-align:-.1em;width:1em}/*!
 *
 * @auto-scaling true
 * @size 4:3 960px 720px
 * @size 16:9 1280px 720px
 * @size 21:9 1680px 720px
 * @size 32:9 2560px 720px
 */div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"]{columns:initial!important;display:block!important;padding:0!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"]::before, div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"]::after, div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="content"]::before, div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="content"]::after{display:none!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container]{all:initial;display:flex;flex-direction:row;height:100%;overflow:hidden;width:100%}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container][data-marpit-advanced-background-direction="vertical"]{flex-direction:column}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"][data-marpit-advanced-background-split] > div[data-marpit-advanced-background-container]{width:var(--marpit-advanced-background-split, 50%)}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"][data-marpit-advanced-background-split="right"] > div[data-marpit-advanced-background-container]{margin-left:calc(100% - var(--marpit-advanced-background-split, 50%))}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container] > figure{all:initial;background-position:center;background-repeat:no-repeat;background-size:cover;flex:auto;margin:0}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="background"] > div[data-marpit-advanced-background-container] > figure > figcaption{position:absolute;border:0;clip:rect(0, 0, 0, 0);height:1px;margin:-1px;overflow:hidden;padding:0;white-space:nowrap;width:1px}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="content"], div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="pseudo"]{background:transparent!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background="pseudo"], div#\:\$p > svg[data-marpit-svg] > foreignObject[data-marpit-advanced-background="pseudo"]{pointer-events:none!important}div#\:\$p > svg > foreignObject > section[data-marpit-advanced-background-split]{width:100%;height:100%}
</style></head><body><div class="bespoke-progress-parent"><div class="bespoke-progress-bar"></div></div><div class="bespoke-marp-osc"><button data-bespoke-marp-osc="prev" tabindex="-1" title="Previous slide">Previous slide</button><span data-bespoke-marp-osc="page"></span><button data-bespoke-marp-osc="next" tabindex="-1" title="Next slide">Next slide</button><button data-bespoke-marp-osc="fullscreen" tabindex="-1" title="Toggle fullscreen (f)">Toggle fullscreen</button><button data-bespoke-marp-osc="presenter" tabindex="-1" title="Open presenter view (p)">Open presenter view</button></div><html><head></head><body><div id=":$p"><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="1" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="1" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="firstH1Page"><img src="https://i.imgur.com/Shai2kG.png" alt="â’¸" class="cc">
<h1 id="advancements-in-cholangiocarcinoma-treatment" tabindex="-1">Advancements in Cholangiocarcinoma Treatment</h1>
<h4 id="speaker-fellow-2-%E6%9E%97%E5%8D%94%E9%9C%86-brmoderator-%E9%99%B3%E6%96%B0%E7%82%AB%E9%86%AB%E5%B8%AB" tabindex="-1"><code>Speaker</code> Fellow 2 æž—å”éœ†  <br><code>Moderator</code> é™³æ–°ç‚«é†«å¸«</h4>
<p><strong>Hsieh-Ting Lin, <a href="mailto:htlin222@kfsyscc.org">htlin222@kfsyscc.org</a></strong></p>
<p><img src="https://i.imgur.com/TLuxHNS.png" alt="" style="height:50px;"></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="2" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="2" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 id="case" tabindex="-1">Case</h1><ol class="agenda"><li class="current"><a href="#case">Case</a></li><li class="after"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="after"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="after"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="3" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="3" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="72-year-old-man---06103741" tabindex="-1">72-year-old man - <code>06103741</code></h2>
<p>he was diagnosed as DM since 2023/9 s/p oral medication control. fast sugar around 100, HbA1c= 6.5%</p>
<ul>
<li>no history of GU infection, hematuria or stone</li>
<li>BWL 20kg: used to be around 73kg as normal body weight, BW around 50s since DM diagnosis. no recovery since then
<ul>
<li>=&gt; <mark>53.7 kg</mark> today ï¼ˆ2023/9 since diagnosed with DM ï¼‰</li>
</ul>
</li>
</ul>
<hr>
<p>Home medication:<br>
metformin 500mg BID<br>
dabigatran 110mg BID<br>
propranolol 10mg BIDprn</p>
<hr>
<p>smoking -<br>
alcohol, beer<br>
betel -<br>
éµè·¯å±€æŠ€è¡“å“¡é€€ä¼‘ <i class="fa-sharp fa-solid fa-bars"></i>ï¼ˆæœ‰ç©ºæ°£æ±™æŸ“çš„æš´éœ² 20-30 å¹´ï¼‰</p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="4" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/794HgYN.png&quot;);background-size:auto 600px;"></figure></div></section></foreignObject><foreignObject width="35%" height="720"><section id="4" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="4" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">72-year-old man - 06103741</div><h3 id="ct-whole-abdomen-plaincontrast" tabindex="-1">CT Whole Abdomen plain&amp;contrast</h3>
<p>Impression and Suggestions</p>
<ol>
<li>Hepatic tumors. Nature to be determined.</li>
<li>Multiple metastatic lymph nodes.</li>
<li>Pulmonary nodules, probably metastasis.</li>
</ol>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="4" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="5" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/Ph6KE9h.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="5" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="5" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text">72-year-old man - 06103741</div><h3 id="mri" tabindex="-1">MRI</h3>
<p>Heterogenous poor enhancing large mass lesion occupying S4 to S8 of the liver with hepatic hilum<br>
compression, left IHD dilatation and multiple metastatic lymphadenopathy at hepatic hilum to bilateral<br>
para-aortic retroperitoneum, portal caval region with necrosis and ill-defined margin, in favor of<br>
extracapsular invasion of lymphadenopathy.</p>
<p><img src="https://i.imgur.com/BvWzvsK.png" alt="" style="height:250px;"></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="5" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="6" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="6" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="active">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="notyet">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h4 id="pathologic-diagnosis" tabindex="-1">Pathologic diagnosis</h4>
<p>Liver, core biopsy: ADENOCARCINOMA. 2024/10/17<br>
HER2: negative, no staining is observed, score: 0 (no overexpression)</p>
<h4 id="treatment-course" tabindex="-1">Treatment course</h4>
<ul>
<li>GC (Gemcitabine+Cisplatin) x8a 2024/04/19 ~ 2024/09/20</li>
<li>Pembrolizumab + Gemcitabine x4 2024/10/29 ~ 2024/12/31</li>
</ul>
<div class="markdown-alert note" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 8a8 8 0 1 1 16 0A8 8 0 0 1 0 8Zm8-6.5a6.5 6.5 0 1 0 0 13 6.5 6.5 0 0 0 0-13ZM6.5 7.75A.75.75 0 0 1 7.25 7h1a.75.75 0 0 1 .75.75v2.75h.25a.75.75 0 0 1 0 1.5h-2a.75.75 0 0 1 0-1.5h.25v-2h-.25a.75.75 0 0 1-.75-.75ZM8 6a1 1 0 1 1 0-2 1 1 0 0 1 0 2Z">
          </path>
        </svg>
        Note
      </span><p><img src="https://i.imgur.com/u8MNdO4.png" alt="" style="height:22px;">:è‚å…§è†½ç®¡ç™Œï¼šå…ˆå‰æ›¾æŽ¥å—éŽè‡³å°‘ä¸€æ¬¡å…¨èº«æ€§æ²»ç™‚å¤±æ•—ï¼Œåˆæœ‰ç–¾ç—…æƒ¡åŒ–ï¼Œç„¡æ³•æ‰‹è¡“åˆ‡é™¤æˆ–æ™šæœŸæˆ–å¾©ç™¼ä¹‹è†½é“ç™Œï¼ˆå«è‚å…§è†½ç®¡ï¼‰ç—…æ‚£ã€‚</p>
</div><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="7" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="7" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Clinical Presentation, Diagnosis" id="clinical-presentation-diagnosis" tabindex="-1">Clinical Presentation, Diagnosis</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="current"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="after"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="after"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="8" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:55%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/EUREPzC.png&quot;);background-size:auto 500px;"></figure></div></section></foreignObject><foreignObject width="45%" height="720"><section id="8" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="8" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:55%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h2 id="characteristics-and-anatomical-features-of-biliary-tract-cancers" tabindex="-1">Characteristics and Anatomical Features of Biliary Tract Cancers</h2>
<p><img src="https://i.imgur.com/BqymkEr.jpeg" alt="" style="height:350px;"></p>
<blockquote><p>Goyal L, Chen CT, Pierce TT, Deshpande V. Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. New England Journal of Medicine. 2021;384(11):1054-1064. doi:10.1056/nejmcpc2027092<br>
Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer discovery. 2017;7(9):943-962. doi:10.1158/2159-8290.CD-17-0245</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="8" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="9" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="9" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="presentation-and-workup" tabindex="-1">Presentation and Workup</h2>
<p><img src="https://i.imgur.com/0gWhnL4.png" alt="" style="height:450px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="10" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:40%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/HYT0cbA.png&quot;);background-size:auto 350px;"></figure></div></section></foreignObject><foreignObject width="60%" height="720"><section id="10" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="10" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:40%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h2 id="btc-staging-per-ajcc-8th" tabindex="-1">BTC Staging, per AJCC 8th</h2>
<br>
<p><img src="https://i.imgur.com/59jlOp7.png" alt="" style="height:350px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers<br>
AJCC Version 9 Cancer Staging System. ACS. Accessed January 11, 2025. <a href="https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/">https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/</a></p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="10" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="11" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="11" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="molecular-testing-in-advanced-biliary-tract-cancer" tabindex="-1">Molecular Testing in Advanced Biliary Tract Cancer</h2>
<p><img src="https://i.imgur.com/0phUebz.png" alt="" style="height:650px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="12" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="12" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">Molecular Testing in Advanced Biliary Tract Cancer</div><h3 id="common-genetic-alterations-in-intrahepatic-and-extrahepatic-cholangiocarcinoma-cca" tabindex="-1">Common genetic alterations in intrahepatic and extrahepatic cholangiocarcinoma (CCA)</h3>
<p><img src="https://i.imgur.com/yRWn0XY.jpeg" alt="" style="height:450px;"></p>
<blockquote><p>Normanno N, Martinelli E, Melisi D, et al. Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open. 2022;7(3). doi:10.1016/j.esmoop.2022.100505</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="13" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="13" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="active">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="notyet">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text">Molecular Testing in Advanced Biliary Tract Cancer</div><h3 id="role-of-liquid-biopsy-for-detection-of-fgfr2-fusions-and-idh1-mutations-in-btc" tabindex="-1">Role of Liquid Biopsy for Detection of FGFR2 Fusions and IDH1 Mutations in BTC?</h3>
<p><img src="https://i.imgur.com/wj4hELM.png" alt="" style="height:450px;"></p>
<blockquote><p>Gouda MA, Subbiah V. Precision oncology for biliary tract tumors: itâ€™s written in blood! Annals of Oncology. 2022;33(12):1209-1211. doi:10.1016/j.annonc.2022.09.157</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="14" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="14" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Overview" id="treatment-overview" tabindex="-1">TREATMENT: Overview</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="current"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="after"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="15" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="15" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="challenges-to-improving-outcomes-in-patients-with-btc" tabindex="-1">Challenges to Improving Outcomes in Patients With BTC</h2>
<div style="font-size: 1.8rem;">
<ul>
<li data-marpit-fragment="1">Most patients (&gt;65%) are diagnosed with unresectable disease</li>
<li data-marpit-fragment="2">Even in patients undergoing curative intent surgery, relapse rates are high (&gt;50%)</li>
<li data-marpit-fragment="3">Many patients with advanced disease are not eligible for targeted therapies as tumor profiling reveals no actionable targets</li>
<li data-marpit-fragment="4">5-yr survival rate: &lt;10% for advanced-stage disease</li>
</ul>
</div>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="16" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="16" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="timeline-of-developments-in-systemic-therapy-of-biliary-tract-cancer" tabindex="-1">Timeline of developments in systemic therapy of biliary tract cancer</h2>
<p><img src="https://i.imgur.com/W8rMXDD.png" alt="" style="height:550px;"></p>
<blockquote><p>Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. The Lancet. 2021;397(10272):428-444. doi:10.1016/S0140-6736(21)00153-7</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="17" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="active">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="notyet">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/NxSKKId.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="17" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="17" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<h2 id="esmo-2024" tabindex="-1">ESMO 2024</h2>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="17" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="18" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="18" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Surgery" id="treatment-surgical" tabindex="-1">Treatment: Surgical</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="current"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="after"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="19" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="19" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-52-year-old-woman" tabindex="-1">A 52-year-old woman</h2>

<p>She presents to the local ED with a 3-week history of having worsening Right upper quadrant abdominal pain. An Ultrasound is performed and suggests cholecystitis. A HIDA scan confirms that she does have <mark>cholecystitis</mark>. A General Surgeon is consulted to evaluate the patient. A <mark>cholecystectomy</mark> is recommended. She undergoes this surgery and tolerates the procedure well. On review of the Pathology report, she was incidentally found to have a <mark>T2 Gallbladder adenocarcinoma</mark> along with Cholecystitis.</p>
<p>The Medicine orders a multiphasic abdominal/pelvic CT scan along with a CT of the Chest. No other sites of disease are seen. What should be done next?</p>
<ul>
<li>A. Gemcitabine + Cisplatin</li>
<li>B. Gemcitabine-based chemoradiation</li>
<li>C. 5-FU-based chemoradiation</li>
<li>D. Take the patient for more surgery</li>
<li>E. Observation</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (D) Take the patient for more surgery</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="20" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="20" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<p><mark>If</mark> a patient undergoes surgery for Cholecystitis and is incidentally found on Pathologic review of the surgical specimen to have Gallbladder adenocarcinoma,</p>
<p><mark>then</mark> the patient needs to undergo a more definitive Oncologic surgery.</p>
<p>This is provided that the patient has been ruled out for metastatic disease.<br>
The definitive Oncologic surgery for Gallbladder cancer entails performing a <mark>hepatic resection + lymphadenectomy +/- bile duct excision</mark>.</p>
<div class="markdown-alert important" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 1.75C0 .784.784 0 1.75 0h12.5C15.216 0 16 .784 16 1.75v9.5A1.75 1.75 0 0 1 14.25 13H8.06l-2.573 2.573A1.458 1.458 0 0 1 3 14.543V13H1.75A1.75 1.75 0 0 1 0 11.25Zm1.75-.25a.25.25 0 0 0-.25.25v9.5c0 .138.112.25.25.25h2a.75.75 0 0 1 .75.75v2.19l2.72-2.72a.749.749 0 0 1 .53-.22h6.5a.25.25 0 0 0 .25-.25v-9.5a.25.25 0 0 0-.25-.25Zm7 2.25v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 9a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Important
      </span><p>More surgery is required for patients with incidentally discovered Gallbladder cancer that is <mark>T1b or greater</mark> and/or a <mark>T1a tumor with positive margins</mark>.</p>
</div><div class="markdown-alert tip" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M8 1.5c-2.363 0-4 1.69-4 3.75 0 .984.424 1.625.984 2.304l.214.253c.223.264.47.556.673.848.284.411.537.896.621 1.49a.75.75 0 0 1-1.484.211c-.04-.282-.163-.547-.37-.847a8.456 8.456 0 0 0-.542-.68c-.084-.1-.173-.205-.268-.32C3.201 7.75 2.5 6.766 2.5 5.25 2.5 2.31 4.863 0 8 0s5.5 2.31 5.5 5.25c0 1.516-.701 2.5-1.328 3.259-.095.115-.184.22-.268.319-.207.245-.383.453-.541.681-.208.3-.33.565-.37.847a.751.751 0 0 1-1.485-.212c.084-.593.337-1.078.621-1.489.203-.292.45-.584.673-.848.075-.088.147-.173.213-.253.561-.679.985-1.32.985-2.304 0-2.06-1.637-3.75-4-3.75ZM5.75 12h4.5a.75.75 0 0 1 0 1.5h-4.5a.75.75 0 0 1 0-1.5ZM6 15.25a.75.75 0 0 1 .75-.75h2.5a.75.75 0 0 1 0 1.5h-2.5a.75.75 0 0 1-.75-.75Z">
          </path>
        </svg>
        Tip
      </span><p>Hepatic resection should be performed to obtain clear margins, which usually consists of removing segments <mark>IVB and V of the liver</mark>. Lymphadenectomy should be performed to clear all lymph nodes from the porta hepatis.</p>
</div><div class="markdown-alert warning" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M6.457 1.047c.659-1.234 2.427-1.234 3.086 0l6.082 11.378A1.75 1.75 0 0 1 14.082 15H1.918a1.75 1.75 0 0 1-1.543-2.575Zm1.763.707a.25.25 0 0 0-.44 0L1.698 13.132a.25.25 0 0 0 .22.368h12.164a.25.25 0 0 0 .22-.368Zm.53 3.996v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 11a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Warning
      </span><p>This patient has a <mark>T2 lesion</mark> which can mean that she has up to a <mark>40%</mark> chance of harboring lymph node metastases. This patient needs a definitive surgery.</p>
</div><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="21" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="21" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-45-year-old-woman" tabindex="-1">A 45-year-old woman</h2>

<p>She presents to the local ED with a <mark>2-week history</mark> of worsening right upper quadrant abdominal pain. She presents with symptoms concerning for Cholecystitis. An Ultrasound and HIDA scan are both ordered which confirm Cholecystitis. A General Surgeon is consulted and performs a <mark>laparoscopic cholecystectomy</mark>.</p>
<p>The Pathology report is reviewed. The gallbladder was inflamed. However, she was incidentally found to have a <mark>T1a (invading the lamina propria) Gallbladder adenocarcinoma</mark>. The surgical margins are <mark>negative</mark>. A CT scan of the C/A/P with IV contrast was negative. What adjuvant therapy should be offered?</p>
<ul>
<li>A. More extensive surgery</li>
<li>B. Chemoradiation (5-FU as sensitizing chemotherapy)</li>
<li>C. FOLFOX</li>
<li>D. Gemcitabine followed by 5-FU/Radiation</li>
<li>E. Observation</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (E) Observation</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="22" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="22" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">A 45-year-old woman</div><h3 id="if-a-patient-undergoes-a-routine-cholecystectomy-for-cholecystitis-and-is-incidentally-found-to-have-a-t1a-lamina-propria" tabindex="-1">If a patient undergoes a routine cholecystectomy for cholecystitis and is incidentally found to have a T1a (lamina propria)</h3>
<div class="markdown-alert tip" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M8 1.5c-2.363 0-4 1.69-4 3.75 0 .984.424 1.625.984 2.304l.214.253c.223.264.47.556.673.848.284.411.537.896.621 1.49a.75.75 0 0 1-1.484.211c-.04-.282-.163-.547-.37-.847a8.456 8.456 0 0 0-.542-.68c-.084-.1-.173-.205-.268-.32C3.201 7.75 2.5 6.766 2.5 5.25 2.5 2.31 4.863 0 8 0s5.5 2.31 5.5 5.25c0 1.516-.701 2.5-1.328 3.259-.095.115-.184.22-.268.319-.207.245-.383.453-.541.681-.208.3-.33.565-.37.847a.751.751 0 0 1-1.485-.212c.084-.593.337-1.078.621-1.489.203-.292.45-.584.673-.848.075-.088.147-.173.213-.253.561-.679.985-1.32.985-2.304 0-2.06-1.637-3.75-4-3.75ZM5.75 12h4.5a.75.75 0 0 1 0 1.5h-4.5a.75.75 0 0 1 0-1.5ZM6 15.25a.75.75 0 0 1 .75-.75h2.5a.75.75 0 0 1 0 1.5h-2.5a.75.75 0 0 1-.75-.75Z">
          </path>
        </svg>
        Tip
      </span><p>A simple cholecystectomy is an adequate treatment for patients who are incidentally found to have <mark>T1a</mark> tumors (provided negative margins are obtained). The long-term survival rates approach 100%.</p>
</div><div class="markdown-alert note" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 8a8 8 0 1 1 16 0A8 8 0 0 1 0 8Zm8-6.5a6.5 6.5 0 1 0 0 13 6.5 6.5 0 0 0 0-13ZM6.5 7.75A.75.75 0 0 1 7.25 7h1a.75.75 0 0 1 .75.75v2.75h.25a.75.75 0 0 1 0 1.5h-2a.75.75 0 0 1 0-1.5h.25v-2h-.25a.75.75 0 0 1-.75-.75ZM8 6a1 1 0 1 1 0-2 1 1 0 0 1 0 2Z">
          </path>
        </svg>
        Note
      </span><p>If a patient undergoes a routine cholecystectomy for cholecystitis and is incidentally found to have a <mark>T1a (lamina propria)</mark> Gallbladder adenocarcinoma on the surgical pathologic specimen and has achieved negative surgical margins, then the patient can undergo observation. There is no role to offer more surgery in this situation.</p>
</div><div class="markdown-alert warning" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M6.457 1.047c.659-1.234 2.427-1.234 3.086 0l6.082 11.378A1.75 1.75 0 0 1 14.082 15H1.918a1.75 1.75 0 0 1-1.543-2.575Zm1.763.707a.25.25 0 0 0-.44 0L1.698 13.132a.25.25 0 0 0 .22.368h12.164a.25.25 0 0 0 .22-.368Zm.53 3.996v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 11a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Warning
      </span><p>However, a patient with an incidentally discovered on cholecystectomy T1a tumor with <mark>positive</mark> surgical margins or <mark>T1b or higher</mark> adenocarcinoma will need to undergo a more definitive/radical surgery. Patients who are incidentally found to have a T1b or greater gallbladder cancer or T1a with positive margins adenocarcinoma should be offered hepatic resection + lymphadenectomy +/- bile duct excision.</p>
</div><div class="markdown-alert important" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 1.75C0 .784.784 0 1.75 0h12.5C15.216 0 16 .784 16 1.75v9.5A1.75 1.75 0 0 1 14.25 13H8.06l-2.573 2.573A1.458 1.458 0 0 1 3 14.543V13H1.75A1.75 1.75 0 0 1 0 11.25Zm1.75-.25a.25.25 0 0 0-.25.25v9.5c0 .138.112.25.25.25h2a.75.75 0 0 1 .75.75v2.19l2.72-2.72a.749.749 0 0 1 .53-.22h6.5a.25.25 0 0 0 .25-.25v-9.5a.25.25 0 0 0-.25-.25Zm7 2.25v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 9a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Important
      </span><p>These patients should then be considered for a clinical trial, observation, chemoradiation or Capecitabine <mark>preferred</mark> as adjuvant therapy.</p>
</div><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="23" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="23" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="active">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="notyet">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="incidental-finding-on-pathologic-review" tabindex="-1">Incidental finding on pathologic review</h2>
<p><img src="https://i.imgur.com/45YTWvj.png" alt="" style="height:450px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Gallbladder Cancer</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="24" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="24" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Chemo" id="treatment-cytotoxic-chemotherapy" tabindex="-1">TREATMENT: Cytotoxic Chemotherapy</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="current"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="after"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="25" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="25" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-62-year-old-man" tabindex="-1">A 62-year-old man</h2>

<p>recently diagnosed with stage <mark>III</mark> Gallbladder adenocarcinoma. A Surgical Oncologist performed a <mark>radical cholecystectomy</mark>, resection of segments IVB and V of his liver and lymphadenectomy. Pathologic analysis of the surgical specimen revealed a <mark>T2 N1 (Stage IIIB)</mark> Adenocarcinoma. A total of 8 lymph nodes were removed and 2 harbored cancer. The surgical resection margins are negative. CT C/A/P with IV contrast showed <mark>no evidence of distant disease</mark>. Which of the following are the preferred adjuvant treatment options for this patient?</p>
<ul>
<li>A. Fluoropyrimidine chemoradiation</li>
<li>B. Capecitabine</li>
<li>C. Clinical trial</li>
<li>D. Observation</li>
<li>E. Choices B or C</li>
</ul>
<p><mark data-marpit-fragment="1"><i class="fa-solid fa-key"></i> Correct Option: E, a.k.a. Choices B or C</mark></p>
<div class="markdown-alert note" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M0 8a8 8 0 1 1 16 0A8 8 0 0 1 0 8Zm8-6.5a6.5 6.5 0 1 0 0 13 6.5 6.5 0 0 0 0-13ZM6.5 7.75A.75.75 0 0 1 7.25 7h1a.75.75 0 0 1 .75.75v2.75h.25a.75.75 0 0 1 0 1.5h-2a.75.75 0 0 1 0-1.5h.25v-2h-.25a.75.75 0 0 1-.75-.75ZM8 6a1 1 0 1 1 0-2 1 1 0 0 1 0 2Z">
          </path>
        </svg>
        Note
      </span><p data-marpit-fragment="2">If the patient in this question had lymph node metastases that were beyond the porta hepatis and/or had distant metastatic disease, then surgical resection would not have been an option.</p>
</div><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="26" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Adjuvant" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="26" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Adjuvant;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Adjuvant</header>
<h2 id="the-swog-0809-study-provided-data-to-support-the-efficacy-of-chemoradiation-and-sequential-chemotherapy" tabindex="-1">The SWOG 0809 study provided data to support the efficacy of chemoradiation and sequential chemotherapy</h2>
<div class="half"><div>
<ul>
<li>Diagnoses: Extrahepatic Cholangiocarcinoma (EHCC) or Gallbladder Adenocarcinoma (GBCA).</li>
<li>Requirements:
<ul>
<li>Radical resection.</li>
<li>Stage pT2-4, N+, positive resection margins, M0.</li>
<li>Performance status 0 to 1.</li>
</ul>
</li>
</ul>
<hr>
<ul>
<li>Total eligible: 79 patients.
<ul>
<li>R0: 54 patients.</li>
<li>R1: 25 patients.</li>
</ul>
</li>
</ul>
</div><div>
<ul>
<li>Treatment regimen:
<ul>
<li>Chemotherapy (4 cycles):
<ul>
<li>Gemcitabine: 1,000 mg/mÂ² IV on days 1 and 8.</li>
<li>Capecitabine: 1,500 mg/mÂ² per day on days 1 to 14.</li>
<li>21-day cycle.</li>
</ul>
</li>
<li>Concurrent chemoradiation:
<ul>
<li>Capecitabine: 1,330 mg/mÂ² per day.</li>
<li>Radiotherapy:
<ul>
<li>45 Gy to regional lymphatics.</li>
<li>54 to 59.4 Gy to tumor bed.</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</div></div>

<blockquote><p>Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of clinical oncologyâ€¯: official journal of the American Society of Clinical Oncology. 2015;33(24):2617-2622. doi:10.1200/JCO.2014.60.2219</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="27" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="27" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">The SWOG 0809 study provided data to support the efficacy of chemoradiation and sequential chemotherapy</div><h3 id="outcome" tabindex="-1">Outcome</h3>
<div class="free"><div>
<p><img src="https://i.imgur.com/qJ4LkzN.png" alt="" style="height:220px;"><br>
<img src="https://i.imgur.com/pGQtF14.png" alt="" style="height:212px;"></p>
</div><div>
<ul>
<li>Survival outcomes:
<ul>
<li>2-year survival for all patients: 65% (95% CI: 53% to 74%).</li>
<li>2-year survival by resection type:
<ul>
<li>R0: 67%.</li>
<li>R1: 60%.</li>
</ul>
</li>
<li>Median overall survival:
<ul>
<li>All patients: 35 months.</li>
<li>R0: 34 months.</li>
<li>R1: 35 months.</li>
</ul>
</li>
</ul>
</li>
<li>Relapse patterns:
<ul>
<li>Local relapse: 14 patients.</li>
<li>Distant relapse: 24 patients.</li>
<li>Combined relapse: 9 patients.</li>
</ul>
</li>
</ul>
</div></div>

<blockquote><p>Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of clinical oncologyâ€¯: official journal of the American Society of Clinical Oncology. 2015;33(24):2617-2622. doi:10.1200/JCO.2014.60.2219</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="28" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Adjuvant" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="28" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Adjuvant;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Adjuvant</header>
<h2 id="capecitabine-compared-with-observation-in-resected-biliary-tract-cancer-bilcap-a-randomised-controlled-multicentre-phase-3-study" tabindex="-1">Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study</h2>

<ul>
<li><strong>Study Population</strong>: 447 patients with biliary tract cancers.</li>
<li><strong>Intervention</strong>: Post-surgical treatment with <strong>capecitabine</strong>.</li>
<li><strong>Key Outcomes</strong>:
<ul>
<li><strong>Survival Benefit</strong>:
<ul>
<li>Capecitabine group: <mark>Median survival = 51 months</mark> (15 months longer).</li>
<li>Observation group: Median survival = 36 months.</li>
</ul>
</li>
<li><strong>Time to Cancer Recurrence</strong>:
<ul>
<li>Capecitabine group: <mark>Median = 25 months</mark>.</li>
<li>Control group: Median = 18 months.</li>
</ul>
</li>
</ul>
</li>
<li><strong>Statistical Analysis</strong>:
<ul>
<li><strong>Overall Survival (OS)</strong>: Did not reach statistical significance in the ITT (Intent-to-Treat) analysis.</li>
</ul>
</li>
</ul>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="29" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-class="flexImg" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="29" style="--paginate:true;--footer:[â– ](#table-of-contents);--class:flexImg;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study</div><h3 id="efficacy" tabindex="-1">Efficacy</h3>

<ul>
<li><img src="https://i.imgur.com/PlHU071.png" alt="" style="height:500px;"></li>
<li><img src="https://i.imgur.com/wNnUFCD.png" alt="" style="height:500px;"></li>
</ul>
<blockquote><p>Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="30" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Adjuvant" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="30" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Adjuvant;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Adjuvant</header>
<h2 id="adjuvant-s-1-jcog1202-ascot" tabindex="-1">Adjuvant S-1, JCOG1202, ASCOT</h2>
<div class="half"><div>
<p>open-label, randomised controlled, phase 3 trial</p>
<ul>
<li><strong>Patient Eligibility</strong> <i class="fa-solid fa-user-check"></i>
<ul>
<li>Aged 20â€“80 years</li>
<li>Histologically confirmed:
<ul>
<li>Extrahepatic cholangiocarcinoma</li>
<li>Gallbladder carcinoma</li>
<li>Ampullary carcinoma</li>
<li>Intrahepatic cholangiocarcinoma</li>
</ul>
</li>
<li>Resection criteria:
<ul>
<li>Resected specimen</li>
<li>No local residual tumour resection or microscopic residual tumour resection</li>
</ul>
</li>
</ul>
</li>
</ul>
</div><div>
<ul>
<li><strong>Randomisation</strong> <i class="fa-solid fa-random"></i>
<ul>
<li>Ratio: 1:1, Groups: Observation, S-1 treatment</li>
</ul>
</li>
<li><strong>Treatment Details (S-1 Group)</strong> <i class="fa-solid fa-pills"></i>
<ul>
<li>Dose based on body surface area:
<ul>
<li>40 mg, 50 mg, or 60 mg</li>
</ul>
</li>
<li>Administration:
<ul>
<li>Orally twice daily</li>
<li>4 weeks of treatment followed by 2 weeks of rest</li>
<li>Total: Four cycles</li>
</ul>
</li>
</ul>
</li>
<li><strong>Endpoints</strong> <i class="fa-solid fa-chart-line"></i>
<ul>
<li>Primary: Overall survival</li>
<li>Assessment: Intention-to-treat basis</li>
</ul>
</li>
</ul>
</div></div>

<blockquote><p>Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet (London, England). 2023;401(10372):195-203. doi:10.1016/S0140-6736(22)02038-4</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="31" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/1VJzGgM.png&quot;);background-size:auto 600px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="31" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="31" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">Adjuvant S-1, JCOG1202, ASCOT</div><h3 id="efficacy-1" tabindex="-1">Efficacy</h3>
<table>
<thead>
<tr>
<th>Group</th>
<th>3-Year OS (%)</th>
<th>Adjusted HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-1</td>
<td>77.1</td>
<td>0.69 (0.51â€“0.94)</td>
<td>0.0080 (one-sided)</td>
</tr>
<tr>
<td>Observation</td>
<td>67.6 (61.0â€“73.3)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
<br>
<table>
<thead>
<tr>
<th>Group</th>
<th>3-Year RFS (%)</th>
<th>HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-1</td>
<td>62.4</td>
<td>0.80 (0.61â€“1.04)</td>
<td>0.088 (two-sided)</td>
</tr>
<tr>
<td>Observation</td>
<td>50.9 (44.1â€“57.2)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
<ul>
<li>Main Grade 3â€“4 Adverse Events:<br>
- Decreased Neutrophil Count: 14% (29 patients)<br>
- Biliary Tract Infection: 7% (15 patients)</li>
</ul>
<blockquote><p>Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet (London, England). 2023;401(10372):195-203. doi:10.1016/S0140-6736(22)02038-4</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="31" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="32" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="32" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="frontline-treatment-of-advanced-btc-abc-02" tabindex="-1">Frontline Treatment of Advanced BTC: ABC-02</h2>

<ul>
<li>
<p>Objective: Evaluate the efficacy of cisplatin plus gemcitabine versus gemcitabine alone in advanced biliary tract cancers.</p>
</li>
<li>
<p>Participants:</p>
<ul>
<li>Total: 410 patients.</li>
<li>Conditions: Locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer.</li>
</ul>
</li>
<li>
<p>Treatment Groups:</p>
<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment Details</th>
<th>Schedule</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin + Gemcitabine</td>
<td>Cisplatin: 25 mg/mÂ² <br> Gemcitabine: 1000 mg/mÂ²</td>
<td>Days 1 and 8, every 3 weeks</td>
<td>8 cycles</td>
</tr>
<tr>
<td>Gemcitabine Alone</td>
<td>Gemcitabine: 1000 mg/mÂ²</td>
<td>Days 1, 8, and 15, every 4 weeks</td>
<td>6 cycles</td>
</tr>
</tbody>
</table>
</li>
</ul>
<blockquote><p>Valle J. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. The New England Journal of Medicine. April 8, 2010. Accessed January 9, 2025. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0908721">https://www.nejm.org/doi/full/10.1056/NEJMoa0908721</a></p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="33" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:35%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/R5C9POo.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="65%" height="720"><section id="33" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="33" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:35%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">Frontline Treatment of Advanced BTC: ABC-02</div><h3 id="results" tabindex="-1">Results</h3>
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Cisplatin + Gemcitabine</th>
<th>Gemcitabine Alone</th>
<th>P-value</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Survival (Median)</td>
<td>11.7 months</td>
<td>8.1 months</td>
<td>&lt; 0.001</td>
<td>Hazard Ratio: 0.64</td>
</tr>
<tr>
<td>Progression-Free Survival</td>
<td>8.0 months</td>
<td>5.0 months</td>
<td>&lt; 0.001</td>
<td>-</td>
</tr>
<tr>
<td>Tumor Control Rate</td>
<td>81.4%</td>
<td>71.8%</td>
<td>0.049</td>
<td>Cisplatin + Gemcitabine significantly improved rates</td>
</tr>
</tbody>
</table>
<h4 id="conclusion" tabindex="-1">Conclusion</h4>
<ul>
<li>The combination of cisplatin and gemcitabine significantly improved overall survival, progression-free survival, and tumor control compared to gemcitabine alone in patients with advanced biliary tract cancers.</li>
</ul>
<blockquote><p>Valle J. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. The New England Journal of Medicine. April 8, 2010. Accessed January 9, 2025. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0908721">https://www.nejm.org/doi/full/10.1056/NEJMoa0908721</a></p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="33" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="34" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/f4gPEmW.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="34" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="34" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<header>1L mBTC</header>
<h2 id="tc1308" tabindex="-1">TC1308</h2>
<p>phase II study of gemcitabine and Sâ€1 in patients with advanced biliary tract cancer, including IHCC, EHCC, GBC, and AVC</p>
<p><img src="https://i.imgur.com/xiWqAVL.png" alt="" style="height:450px;"></p>
<blockquote><p>Chiang NJ, Chen MH, Yang SH, et al. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study. Liver internationalâ€¯: official journal of the International Association for the Study of the Liver. 2020;40(10):2535-2543. doi:10.1111/liv.14538</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="34" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="35" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/JwBvLPg.png&quot;);background-size:auto 550px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="35" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="35" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content"><blockquote><p>TCOG. ç ”ç™¼å°ç£è†½é“ç™Œå°ˆå±¬å…ç–«åŒ–ç™‚è¤‡æ–¹(NGS) é™ä½Žå‰¯ä½œç”¨ æ•´é«”å­˜æ´»æœŸå»¶é•·è‡³ 19 å€‹æœˆ â€“ National Institute of Cancer Research. Accessed January 13, 2025. <a href="https://nicr.nhri.edu.tw/en/110221press/">https://nicr.nhri.edu.tw/en/110221press/</a></p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="35" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="36" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="36" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L mBTC</header>
<h2 id="folfox-in-btc-abc-06" tabindex="-1">FOLFOX in BTC (ABC-06)</h2>
<div class="free"><div>
<ul>
<li><strong>Histologically or cytologically verified</strong>: Locally advanced or metastatic biliary tract cancer.</li>
<li><strong>Documented progression</strong>: Radiological evidence of disease progression following first-line cisplatin and gemcitabine chemotherapy.</li>
<li><strong>ECOG Performance Status</strong>: Score of 0â€“1.</li>
<li><strong>Randomization</strong>: Participants randomly assigned (1:1) to:
<ul>
<li>Active symptom control (ASC) + FOLFOX.</li>
<li>ASC alone.</li>
</ul>
</li>
<li><strong>FOLFOX Administration</strong>:
<ul>
<li>Administered <strong>intravenously</strong> every <strong>2 weeks</strong>.</li>
<li>Maximum of <strong>12 cycles</strong>.</li>
</ul>
</li>
</ul>
</div><div>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase</td>
<td>3</td>
</tr>
<tr>
<td>Trial Type</td>
<td>Randomised</td>
</tr>
<tr>
<td>Location</td>
<td>UK</td>
</tr>
<tr>
<td>Patient Age</td>
<td>â‰¥18 years</td>
</tr>
<tr>
<td>Cancer Type</td>
<td>Biliary</td>
</tr>
<tr>
<td>Performance</td>
<td>0â€“1</td>
</tr>
<tr>
<td>Treatment</td>
<td>FOLFOX</td>
</tr>
<tr>
<td>Primary Endpoint</td>
<td>Survival</td>
</tr>
</tbody>
</table>
</div></div>

<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="37" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="active">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="notyet">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/mZU0gE0.png&quot;);background-size:auto 500px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="37" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="37" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">FOLFOX in BTC (ABC-06)</div><h3 id="efficacy-2" tabindex="-1">Efficacy</h3>
<p><img src="https://i.imgur.com/thbONbf.png" alt="" style="height:400px;"></p>
<p>ABC-06 study show that FOLFOX can improve OS with advanced biliary tract cancer who have been previously treated with cisplatin and gemcitabine.</p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="37" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="38" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="38" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="ICI" id="treatment-immunotherapy" tabindex="-1">TREATMENT: Immunotherapy</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="before"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="current"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="after"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="39" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="39" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-64-year-old-woman-with-metastatic-gallbladder-cancer" tabindex="-1">A 64-year-old woman with metastatic gallbladder cancer</h2>

<p>A CT scan of the C/A/P with IV contrast showed disease in her gallbladder along with several liver lesions.<br>
A biopsy of a liver lesion was performed. Pathology confirmed metastatic gallbladder cancer</p>
<p>A CMP reveals that her direct bilirubin is 4 mg/dl.<br>
A liver lesion is causing obstruction of a bile duct. She undergoes an ERCP with stent placement. Her hyperbilirubinemia resolved. She is not interested in a clinical trial. She has an outstanding performance status. NGS not reveal any actionable mutations. <mark>The tumor is MSS and TMB low</mark></p>
<p><strong>Which of the following treatment regimens should be offered?</strong></p>
<ul>
<li>A. Gemcitabine + 5-FU</li>
<li>B. FOLFIRINOX</li>
<li>C. Gemcitabine + Nab-Paclitaxel</li>
<li>D. Gemcitabine + Cisplatin + Durvalumab</li>
<li>E. Pembrolizumab</li>
</ul>
<p><mark data-marpit-fragment="1"><i class="fa-solid fa-key"></i> Correct Option: (D) Gemcitabine + Cisplatin + Durvalumab</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="40" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="40" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="topaz-1-durvalumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc" tabindex="-1">TOPAZ-1: Durvalumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</h2>

<p><img src="https://i.imgur.com/BTMZcXl.png" alt="" style="height:450px;"></p>
<blockquote><p>Burris. ASCO 2022. Abstr 4070. Oh. ASCO GI 2022. Abstr 378.</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="41" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="41" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<div class="h2text firsth3afterh2">TOPAZ-1: Durvalumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</div><h3 id="results-1" tabindex="-1">Results</h3>
<p><img src="https://i.imgur.com/IVPYsSe.jpeg" alt="" style="height:550px;"></p>
<blockquote><p>Burris. ASCO 2022. Abstr 4070. Oh. ASCO GI 2022. Abstr 378.</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="42" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="42" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-54-year-old-man" tabindex="-1">A 54-year-old man</h2>

<p>A 54-year-old man  with no significant past medical history has been recently diagnosed with <mark>Stage IV Extrahepatic Cholangiocarcinoma</mark> CT imaging of the Chest/Abdomen/Pelvis revealed bilateral <mark>liver and lung metastases</mark>. There is also a mass seen in the extrahepatic bile duct.</p>
<p>Interventional Radiology performs a biopsy of a lung lesion that confirms the diagnosis. <mark>NGS testing of the tumor reveals no actionable mutations</mark>. The tumor is <mark>MSS and TMB low</mark>. Which of the following immunotherapy medications can be given alongside Gemcitabine + Cisplatin as part of frontline treatment?</p>
<ul>
<li>A. Nivolumab</li>
<li>B. Pembrolizumab</li>
<li>C. Atezolizumab</li>
<li>D. Ipilimumab</li>
<li>E. Toripalimab</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (B) Pembrolizumab, mOS was 12.7 months vs 10.9 months</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="43" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="43" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="keynote-966-pembrolizumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc" tabindex="-1">KEYNOTE-966: Pembrolizumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</h2>

<p><img src="https://i.imgur.com/B5YnRtd.png" alt="" style="height:450px;"></p>
<blockquote><p>Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="44" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/Gkmty15.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="35%" height="720"><section id="44" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="44" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;--marpit-advanced-background-split:65%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<div class="h2text firsth3afterh2">KEYNOTE-966: Pembrolizumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</div><h3 id="efficacy-3" tabindex="-1">Efficacy</h3>
<p><img src="https://i.imgur.com/zcIgxhR.png" alt="" style="height:150px;"></p>
<p>The median OS was <mark>12.7 months</mark> (95% CI: 11.5, 13.6) and <mark>10.9 months</mark> (95% CI: 9.9, 11.6) in the respective arms.</p>
<blockquote><p>Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="44" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="45" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="45" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="what-did-we-learn-from-topaz-1-and-keynote-966" tabindex="-1">What did we learn from TOPAZ-1 and KEYNOTE-966</h2>
<table>
<thead>
<tr>
<th>Aspect</th>
<th>TOPAZ-1</th>
<th>KEYNOTE-966</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Size</td>
<td>685 patients</td>
<td>1,069 patients</td>
</tr>
<tr>
<td>Overall Survival (OS)</td>
<td>12.8 vs. 11.5 months (HR=0.80, P=0.021)</td>
<td>12.7 vs. 10.9 months (HR=0.83, P=0.0034)</td>
</tr>
<tr>
<td>Progression-Free Survival (PFS)</td>
<td>Improved (exact numbers not specified)</td>
<td>6.5 vs. 5.6 months (P=0.023)</td>
</tr>
<tr>
<td>Subgroup Representativeness</td>
<td>More representation from Asia, less intrahepatic tumors</td>
<td>Higher intrahepatic tumor cases, more patients from outside Asia (55%)</td>
</tr>
<tr>
<td>Chemotherapy Duration</td>
<td>Chemotherapy discontinued after 8 cycles; Durvalumab continued in the intervention arm</td>
<td>Chemotherapy continued longer (up to best response)</td>
</tr>
<tr>
<td>Immune-Mediated Adverse Events</td>
<td>Any grade: 12.7% (Durvalumab) vs. 4.7% (Placebo); Grade 3/4: 2.4% vs. 1.5%</td>
<td>Any grade: 22% (Pembrolizumab) vs. 13% (Placebo); Grade 3/4: 7% vs. 4%</td>
</tr>
<tr class="emphasize">
<td><strong>PD-L1 Combined Positive Score (CPS)</strong></td>
<td>Benefits observed regardless of CPS levels</td>
<td>Benefits observed regardless of CPS levels</td>
</tr>
<tr>
<td>Geographic Distribution</td>
<td>Higher proportion of Asian participants</td>
<td>More globally distributed; 55% of participants outside Asia</td>
</tr>
<tr class="emphasize">
<td><strong>Tumor Subtype Coverage</strong></td>
<td>Benefits seen in both intrahepatic and extrahepatic tumors</td>
<td>Benefits more pronounced in intrahepatic tumors</td>
</tr>
</tbody>
</table>
<blockquote><p>Almhanna K. Immune checkpoint inhibitors in combination with chemotherapy for patients with biliary tract cancer: what did we learn from TOPAZ-1 and KEYNOTE-966. Translational Cancer Research. 13(1). doi:10.21037/tcr-23-1763</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="46" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-class="flexImg" data-header="1L mBTC" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="46" style="--paginate:true;--footer:[â– ](#table-of-contents);--class:flexImg;--header:1L mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="active">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="notyet">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>1L mBTC</header>
<h2 id="gemcitabine-and-s-1-plus-nivolumab-in-advanced-biliary-tract-cancer-a-phase-ii-t1219-study" tabindex="-1">Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study</h2>

<p><mark>NGS</mark> nivolumab 240 mg and 800 mg/m2 gemcitabine on day 1 plus daily 80/100/120 mg of S-1 (based on body surface area) on days 1 to 10, in a 2-week cycle.</p>
<ul>
<li><img src="https://i.imgur.com/Hv1piC8.png" alt="" style="height:400px;"></li>
<li><img src="https://i.imgur.com/s1BnTeK.png" alt="" style="height:400px;"></li>
</ul>
<blockquote><p>Chiang NJ, Tan KT, Bai LY, et al. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical Cancer Research. 2022;28(19):4248-4257. doi:10.1158/1078-0432.CCR-22-1152</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="47" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="47" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 data-sm="Target" id="treatment-target" tabindex="-1">TREATMENT: Target</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="before"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="before"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="current"><a href="#treatment-target">TREATMENT: Target</a></li><li class="after"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="48" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="48" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="esmo-2024-1" tabindex="-1">ESMO 2024</h2>
<p><img src="https://i.imgur.com/dhf9tqS.png" alt="" style="height:450px;"></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="49" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="49" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-72-year-old-man" tabindex="-1">A 72-year-old man</h2>

<p>A 72-year-old man to start second-line treatment for his metastatic gallbladder cancer. He was diagnosed with metastatic gallbladder cancer 1 year ago.</p>
<p>A baseline CT C/A/P revealed bilateral <mark>liver metastases along with a gallbladder mass</mark>. At that time, he underwent a palliative cholecystectomy due to severe right upper quadrant pain. Pathologic analysis of the surgical specimen revealed Gallbladder adenocarcinoma.</p>
<p>He was started on palliative chemotherapy with <mark>Gemcitabine + Cisplatin + Durvalumab</mark>. He had a partial response that lasted for one year prior to disease progression. NGS testing of his tumor revealed an <mark>FGFR2 fusion</mark>. His performance status remains robust outside of Grade I neuropathy that is from his prior exposure to Cisplatin. Which therapy should be recommended?</p>
<ul>
<li>A. Hospice</li>
<li>B. FOLFIRINOX</li>
<li>C. Nivolumab</li>
<li>D. Nab-Paclitaxel</li>
<li>E. Pemigatinib</li>
</ul>
<p><mark data-marpit-fragment="1"><i class="fa-solid fa-key"></i> Correct Option: E, Pemigatinib</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="50" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="50" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="approved-fgfr-inhibitors-for-advanced-cholangiocarcinoma-key-phase-ii-trials" tabindex="-1">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</h2>

<p><img src="https://i.imgur.com/Oz9unrE.png" alt="" style="height:450px;"></p>
<blockquote><p>Abou-Alfa. Lancet Oncol. 2020;21:671. Goyal. NEJM. 2023;388:228. Pemigatinib PI. Futibatinib PI.</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="51" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="51" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<div class="h2text firsth3afterh2">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</div><h3 id="nhi" tabindex="-1">NHI</h3>
<ul>
<li>Pemigatinib ï¼ˆå¦‚ Pemazyreï¼‰ï¼š(112/5/1ã€113/6/1)
<ol>
<li>é©ç”¨æ–¼æˆäººæŽ¥å—éŽå…¨èº«æ€§è—¥ç‰©æ²»ç™‚ã€è…«ç˜¤å…·æœ‰ FGFR2 èžåˆæˆ–é‡æŽ’ã€ä¸å¯æ‰‹è¡“åˆ‡é™¤çš„å±€éƒ¨æ™šæœŸæˆ–è½‰ç§»æ€§è‚å…§è†½ç®¡ç™Œã€‚</li>
<li>éœ€ç¶“äº‹å‰å¯©æŸ¥æ ¸å‡†å¾Œä½¿ç”¨ï¼Œåˆæ¬¡ç”³è«‹éœ€æª¢é™„è…«ç˜¤çµ„ç¹”å…·æœ‰ FGFR2 åŸºå› èžåˆæˆ–é‡æŽ’ä¹‹åŸºå› è®Šç•°æª¢æ¸¬å ±å‘Šï¼Œä¸”éœ€ç¬¦åˆå…¨æ°‘å¥åº·ä¿éšªè—¥å“çµ¦ä»˜è¦å®šä¹‹é€šå‰‡åäºŒã€‚(113/6/1)</li>
<li>æ ¸å‡†å¾Œæ¯ 12 é€±éœ€å†æ¬¡ç”³è«‹ï¼Œå†æ¬¡ç”³è«‹æ™‚éœ€æª¢é™„ï§æ•ˆè©•ä¼°è³‡ï¦¾è­‰å¯¦ç„¡ç–¾ç—…æƒ¡åŒ–ï¼Œæ‰å¯ç¹¼çºŒä½¿ç”¨ã€‚</li>
<li>æ¯æ—¥é™è™•æ–¹ 1 ç²’ã€‚</li>
</ol>
</li>
</ul>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="52" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="52" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<div class="h2text">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</div><h3 id="a-78-year-old-feman-iv-intrahepatic-bile-duct-cancer" tabindex="-1">A 78-year-old feman, IV Intrahepatic bile duct cancer</h3>

<p>Next generation sequencing of the tumor was performed and revealed an <mark>FGFR2 fusion</mark>.<br>
She was <mark>treated with Gemcitabine, Cisplatin and Durvalumab x 6 cycles</mark> and she had a near complete response. She was then placed on maintenance therapy with Gemcitabine + Durvalumab. She had stable disease that lasted for 18 months prior to disease progression. She tolerated therapy well but has <mark>residual neuropathy from Cisplatin</mark>. While she would <mark>like to continue therapy</mark>, she would like to avoid medications that may cause worsening of her neuropathy. Which therapy should be offered?</p>
<ul>
<li>A. Futibatinib</li>
<li>B. Pemigatinib</li>
<li>C. Regorafenib</li>
<li>D. Choices A or B</li>
<li>E. All of the above</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: D, Choices A or B</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="53" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="53" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="fgfr-inhibitors-unique-class-specific-adverse-events" tabindex="-1">FGFR Inhibitors: Unique Class-Specific Adverse Events</h2>

<p><img src="https://i.imgur.com/P37IaVI.jpeg" alt="" style="height:420px;"></p>
<div class="markdown-alert warning" dir="auto">
      <span>
        <svg class="markdown-alert-icon" viewBox="0 0 16 16" version="1.1" width="16" height="16" aria-hidden="true">
          <path d="M6.457 1.047c.659-1.234 2.427-1.234 3.086 0l6.082 11.378A1.75 1.75 0 0 1 14.082 15H1.918a1.75 1.75 0 0 1-1.543-2.575Zm1.763.707a.25.25 0 0 0-.44 0L1.698 13.132a.25.25 0 0 0 .22.368h12.164a.25.25 0 0 0 .22-.368Zm.53 3.996v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 1.5 0ZM9 11a1 1 0 1 1-2 0 1 1 0 0 1 2 0Z">
          </path>
        </svg>
        Warning
      </span><p><mark>Hyperphosphatemia</mark> is the most common AE<br>
All patients should have a baseline <mark>eye exam</mark> before therapy initiation</p>
</div><blockquote><p>Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer treatment reviews. 2021;95:102170. doi:10.1016/j.ctrv.2021.102170</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="54" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-class="flexList" data-heading-divider="3" data-theme="main" lang="en-US" class="flexList" data-marpit-pagination="54" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--class:flexList;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="idh1-mutations-in-icc" tabindex="-1">IDH1 Mutations in ICC</h2>

<p>68-year-old man, metastatic bile duct cancer.<br>
At that time, he was started on <mark>Gemcitabine + Cisplatin + Durvalumab</mark>. He had a partial response.<br>
He was then started on treatment with <mark>FOLFOX</mark>. He had another partial response that lasted for 1 year prior to disease progression.<br>
A recent restaging CT scan of the C/A/P shows two new liver lesions.</p>

<ul>
<li>
<p>Next Generation Sequencing of the tumor reveals the following:</p>
<ul>
<li>No FGFR2 fusion, No NTRK gene fusion</li>
<li>No BRAF mutation</li>
<li>MSS, TMB low</li>
<li><mark>IDH1 mutated</mark></li>
</ul>
</li>
<li>
<p>Which treatment should be offered?</p>
<ul>
<li>A. Enasidenib</li>
<li>B. Ivosidenib</li>
<li>C. Regorafenib</li>
<li>D. Lenalidomide</li>
<li>E. Futibatinib</li>
</ul>
</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: B</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="55" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="55" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="claridhy-ivosidenib-vs-placebo-in-previously-treated-cholangiocarcinoma-with-idh1-mutation" tabindex="-1">ClarIDHy: Ivosidenib vs Placebo in Previously Treated Cholangiocarcinoma With <mark>IDH1</mark> Mutation</h2>

<p>An international, double-blind, randomized phase III trial</p>
<p><img src="https://i.imgur.com/mtnjSdF.png" alt="" style="height:450px;"></p>
<blockquote><p>Abou-Alfa. Lancet Oncol. 2020;21:796. Zhu. JAMA Oncol. 2021;e213836.</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="56" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="56" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-75-year-old-feman" tabindex="-1">A 75-year-old feman</h2>

<p>start second-line therapy for her Metastatic extrahepatic cholangiocarcinoma. She was started on frontline therapy with Cisplatin + Gemcitabine + Pembrolizumab. She had a partial response to treatment that lasted for 6 months prior to disease progression. Due to the side effects that she endured from chemotherapy, she is not interested in being treated with this class of medication going forward.</p>
<p>A recent restaging scan showed enlargement of her known liver lesions and the development of new lung lesions. A repeat biopsy of a liver lesion is performed that confirms Cholangiocarcinoma. Next Generation Sequencing is sent for on this tumor sample. <mark>A BRAF V600E mutation is seen</mark>. The only other mutation seen is a TP53 mutation. The patient does have a robust performance status. Which therapy is the best regimen to start at this time?</p>
<ul>
<li>A. FOLFOX</li>
<li>B. Lenvatinib + Pembrolizumab</li>
<li>C. Dabrafenib + Trametinib</li>
<li>D. Vemurafenib + Cobimetinib</li>
<li>E. Pralsetinib</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (C) Dabrafenib + Trametinib</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="57" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-class="flexImg" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="57" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--class:flexImg;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="dabrafenib--trametinib-for-brafv600e%E2%80%93mutated-btc-tumor-size-change-and-response-duration" tabindex="-1">Dabrafenib + Trametinib for BRAF<sup>V600E</sup>â€“Mutated BTC: Tumor Size Change and Response Duration</h2>

<p><mark>ROAR</mark>: phase 2, open-label, single-arm, multicentre basket trial</p>

<ul>
<li><img src="https://i.imgur.com/hWIC0b8.png" alt="" style="height:350px;"></li>
<li><img src="https://i.imgur.com/LShcibZ.png" alt="" style="height:350px;"></li>
</ul>
<blockquote><p>Subbiah V, Lassen U, Ã‰lez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. The Lancet Oncology. 2020;21(9):1234-1243. doi:10.1016/S1470-2045(20)30321-1</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="58" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="Case Challenge" data-class="flexList" data-heading-divider="3" data-theme="main" lang="en-US" class="flexList" data-marpit-pagination="58" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:Case Challenge;--class:flexList;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>Case Challenge</header>
<h2 id="a-74-year-old-man" tabindex="-1">A 74-year-old man</h2>

<p>One year ago, he was diagnosed with <mark>Stage IV disease</mark>. The tumor originated in his gallbladder. A baseline CT C/A/P with IV contrast showed bilateral liver metastases along with 4 pulmonary lesions. A biopsy of a lung lesion confirmed bile duct cancer. <mark>Testing of the tumor revealed that the Her2=3+ on IHC</mark>.</p>
<p>s/p <mark>Gemcitabine + Cisplatin + Durvalumab</mark>. He had a partial response to treatment that lasted for 1 year prior to disease progression. The Cisplatin was stopped after 6 cycles of therapy as he developed Grade 2 neuropathy. The patient was placed on maintenance therapy with Gemcitabine + Durvalumab.</p>

<ul>
<li>NGS testing of the tumor revealed the following:
<ul>
<li>No FGFR2 fusion</li>
<li>No NTRK gene fusion, No RET gene fusion</li>
<li>BRAF wild-type, IDH1 wild-type</li>
<li>TMB: Low MSS</li>
</ul>
</li>
<li>For second-line therapy, what should be offered?
<ul>
<li>A. FOLFOXIRI</li>
<li>B. Regorafenib</li>
<li>C. Paclitaxel + Ramucirumab</li>
<li>D. Trastuzumab deruxtecan</li>
<li>E. FOLFOX + Trastuzumab</li>
</ul>
</li>
</ul>
<p data-marpit-fragment="1"><mark><i class="fa-solid fa-key"></i> Correct Option: (D) Trastuzumab deruxtecan</mark></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="59" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="59" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="destiny-pantumor02-phase-ii-trial" tabindex="-1">DESTINY-PanTumor02 Phase II Trial</h2>

<p><img src="https://i.imgur.com/m9KHVGH.png" alt="" style="height:450px;"></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="60" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-class="flexImg" data-heading-divider="3" data-theme="main" lang="en-US" class="flexImg" data-marpit-pagination="60" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--class:flexImg;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<div class="h2text firsth3afterh2">DESTINY-PanTumor02 Phase II Trial</div><h3 id="outcome-1" tabindex="-1">Outcome</h3>

<ul>
<li><img src="https://i.imgur.com/QK7FLJT.png" alt="" style="height:450px;"></li>
<li><img src="https://i.imgur.com/EoOv2uV.png" alt="" style="height:450px;"></li>
</ul>
<blockquote><p>Meric-Bernstam F. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of Clinical Oncology. Published online January 1, 2024.</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="61" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/Us4tXYh.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="61" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="61" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<header>2L+ mBTC</header>
<h2 id="zanidatamab-zw25-a-humanized-igg1-like-biparatopic-antibody" tabindex="-1">Zanidatamab (ZW25): A Humanized IgG1-like Biparatopic Antibody</h2>

<ul>
<li>Zanidatamab is a HER2-targeted bispecific antibody that binds 2 separate HER2 epitopes, resulting in multiple mechanisms of action</li>
<li>Zanidatamab binds 2 HER2 domains targeted by trastuzumab (ECD4) and pertuzumab (ECD2)</li>
<li>Cross links multiple HER2 receptors</li>
<li>Improves HER2 internalization and degradation</li>
<li>Preclinical studies showed growth inhibition of cancer cell lines with wide range of HER2 expression</li>
</ul>
<blockquote><p>Weisser. Nature Commun. 2023;14:1394. Tarantino. Explor Antitumor Ther. 2021;2:139. DiPeri. Cancer Discov. 2024;[Epub].</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="61" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="62" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:45%;" data-marpit-pagination-total="72" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/IHmkAkr.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="55%" height="720"><section id="62" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="62" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;--marpit-advanced-background-split:45%;" data-marpit-pagination-total="72" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<header>2L+ mBTC</header>
<h2 id="herizon-btc-01-zanidatamab-for-previously-treated-her2%E2%80%90amplified-biliary-tract-cancer" tabindex="-1">HERIZON-BTC-01: Zanidatamab for Previously Treated HER2â€Amplified Biliary Tract Cancer</h2>
<p><img src="https://i.imgur.com/6C1lHpI.png" alt="" style="height:300px;"></p>

<p><img class="emoji" draggable="false" alt="ðŸ‘€" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@15.1.0/assets/svg/1f440.svg" data-marp-twemoji=""> HERIZON-BTC-302: First-Line Zanidatamab + SoC Therapy for Patients With Advanced HER2+ BTC</p>
<blockquote><p>Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. The Lancet Oncology. 2023;24(7):772-782. doi:10.1016/S1470-2045(23)00242-5</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="62" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="63" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-header="2L+ mBTC" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="63" style="--paginate:true;--footer:[â– ](#table-of-contents);--header:2L+ mBTC;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="active">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="notyet">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<header>2L+ mBTC</header>
<h2 id="incidence-of-therapeutic-targets-in-advanced-biliary-tract-cancers" tabindex="-1">Incidence of Therapeutic Targets in Advanced Biliary Tract Cancers</h2>
<p><img src="https://i.imgur.com/Xpud4I2.png" alt="" style="height:450px;"></p>
<blockquote><p>NCCN Guidelines Version 5.2024 Biliary Tract Cancers</p>
</blockquote><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="64" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="64" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" class="blue">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h1 id="takeaway" tabindex="-1">Takeaway</h1><ol class="agenda"><li class="before"><a href="#case">Case</a></li><li class="before"><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a></li><li class="before"><a href="#treatment-overview">TREATMENT: Overview</a></li><li class="before"><a href="#treatment-surgical">Treatment: Surgical</a></li><li class="before"><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a></li><li class="before"><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a></li><li class="before"><a href="#treatment-target">TREATMENT: Target</a></li><li class="current"><a href="#takeaway">Takeaway</a></li></ol><footer class="title_as_footer">Advancements in Cholangiocarcinoma Treatment</footer>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="65" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="65" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="precision-oncology-is-key-for-management-of-advanced-cholangiocarcinoma" tabindex="-1">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</h2>
<p><img src="https://i.imgur.com/NVsMu4z.png" alt="" style="height:450px;"></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="66" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/0IqaIuN.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="66" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="66" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content"><footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="66" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="67" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/ZtIKKw1.png&quot;);background-size:auto 550px;"></figure><figure style="background-image:url(&quot;https://i.imgur.com/I3m9pCu.png&quot;);background-size:auto 550px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="67" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="67" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<div class="h2text firsth3afterh2">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</div><h3 id="early-stage" tabindex="-1">Early Stage</h3>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="67" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="68" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/raSeYZo.png&quot;);background-size:auto 450px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="68" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="68" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<div class="h2text">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</div><h3 id="advanced-or-metastatic-stage" tabindex="-1">Advanced or Metastatic Stage</h3>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="68" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="69" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="background">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/rDbUGc4.png&quot;);background-size:auto 350px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="69" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="69" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72" data-marpit-advanced-background="content">
<div class="h2text">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</div><h3 id="advanced-or-metastatic-stage-relapse-and-refractory" tabindex="-1">Advanced or Metastatic Stage: relapse and refractory</h3>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="69" style="" data-marpit-pagination-total="72" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="70" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="70" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="tldr" tabindex="-1">TL;DR</h2>
<br>
<table>
<thead>
<tr>
<th>åˆ†é¡ž</th>
<th>ç¾è¡Œåœ‹éš›æ¨™æº–æ²»ç™‚</th>
<th>å…¶ä»–æ–°ç™‚æ³•</th>
</tr>
</thead>
<tbody>
<tr>
<td>ç¬¬ä¸€ç·š</td>
<td>1. GC è™•æ–¹ï¼ˆå¥ä¿çµ¦ä»˜ï¼‰ï¼š<br>gemcitabineï¼ˆå¥ç™‚ï¼‰+ cisplatinï¼ˆé †é‰‘ï¼‰</td>
<td>1. GC è™•æ–¹ + durvalumab</td>
</tr>
<tr>
<td></td>
<td>2. æ”¹è‰¯åž‹ GS è™•æ–¹ï¼ˆTS-1 éœ€è‡ªè²»ï¼‰ï¼š<br>gemcitabineï¼ˆå¥ç™‚ï¼‰+ æ„›æ–¯æ–½é”ï¼ˆTS-1ï¼‰</td>
<td>2. GS è™•æ–¹ + nivolumab</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. GC è™•æ–¹ + pembrolizumab</td>
</tr>
<tr>
<td>ç¬¬äºŒç·š</td>
<td>FOLFOXï¼ˆ5-FU/leucovorin/oxaliplatinï¼‰ï¼ˆoxaliplatin éœ€è‡ªè²»ï¼‰</td>
<td>- IDH åŸºå› è®Šç•°å¯ç”¨ TIBSOVOï¼ˆivosidenib éŒ åŠ‘ï¼‰</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- FGFR2 åŸºå› èžåˆ/é‡æŽ’è€…ï¼š<br>pemigatinibï¼ˆç¬¬äºŒç·šå¥ä¿æš«æ™‚æ€§çµ¦ä»˜ï¼‰ï¼Œinfigratinibï¼Œfutibatinib</td>
</tr>
</tbody>
</table>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="71" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-class="center" data-heading-divider="3" data-theme="main" lang="en-US" class="center" data-marpit-pagination="71" style="--paginate:true;--footer:[â– ](#table-of-contents);--class:center;--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 class="animated-text" id="thank-you" tabindex="-1">Thank you</h2>
<hr>
<h5 is="marp-h5" data-auto-scaling="" id="advancements-in-cholangiocarcinoma-treatment-1" tabindex="-1">Advancements in Cholangiocarcinoma Treatment</h5>
<hr>
<h4 id="lets-take-some-questions" tabindex="-1">Letâ€™s Take Some Questions</h4>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="72" data-paginate="true" data-footer="[â– ](#table-of-contents)" data-heading-divider="3" data-theme="main" lang="en-US" data-marpit-pagination="72" style="--paginate:true;--footer:[â– ](#table-of-contents);--heading-divider:3;--theme:main;" data-marpit-pagination-total="72">
            <div class="menubar top ready" id="menubartop">
                <ul class="menu" data-simplemenu-auto="">
                    <li class="done">
                    <a href="#case" data-sm="Case">Case</a>
                </li><li class="done">
                    <a href="#clinical-presentation-diagnosis" data-sm="Clinical Presentation, Diagnosis">Clinical Presentation, Diagnosis</a>
                </li><li class="done">
                    <a href="#treatment-overview" data-sm="Overview">Overview</a>
                </li><li class="done">
                    <a href="#treatment-surgical" data-sm="Surgery">Surgery</a>
                </li><li class="done">
                    <a href="#treatment-cytotoxic-chemotherapy" data-sm="Chemo">Chemo</a>
                </li><li class="done">
                    <a href="#treatment-immunotherapy" data-sm="ICI">ICI</a>
                </li><li class="done">
                    <a href="#treatment-target" data-sm="Target">Target</a>
                </li><li class="active">
                    <a href="#takeaway" data-sm="Takeaway">Takeaway</a>
                </li>
                </ul>
            </div>
<h2 id="table-of-contents" tabindex="-1">Table of Contents</h2>
<p></p><div class="table-of-contents"><ul><li><a href="#advancements-in-cholangiocarcinoma-treatment">Advancements in Cholangiocarcinoma Treatment</a></li><li><a href="#case">Case</a><ul><li><a href="#72-year-old-man---06103741">72-year-old man - 06103741</a></li></ul></li><li><a href="#clinical-presentation-diagnosis">Clinical Presentation, Diagnosis</a><ul><li><a href="#characteristics-and-anatomical-features-of-biliary-tract-cancers">Characteristics and Anatomical Features of Biliary Tract Cancers</a></li><li><a href="#presentation-and-workup">Presentation and Workup</a></li><li><a href="#btc-staging-per-ajcc-8th">BTC Staging, per AJCC 8th</a></li><li><a href="#molecular-testing-in-advanced-biliary-tract-cancer">Molecular Testing in Advanced Biliary Tract Cancer</a></li></ul></li><li><a href="#treatment-overview">TREATMENT: Overview</a><ul><li><a href="#challenges-to-improving-outcomes-in-patients-with-btc">Challenges to Improving Outcomes in Patients With BTC</a></li><li><a href="#timeline-of-developments-in-systemic-therapy-of-biliary-tract-cancer">Timeline of developments in systemic therapy of biliary tract cancer</a></li><li><a href="#esmo-2024">ESMO 2024</a></li></ul></li><li><a href="#treatment-surgical">Treatment: Surgical</a><ul><li><a href="#a-52-year-old-woman">A 52-year-old woman</a></li><li><a href="#a-45-year-old-woman">A 45-year-old woman</a></li><li><a href="#incidental-finding-on-pathologic-review">Incidental finding on pathologic review</a></li></ul></li><li><a href="#treatment-cytotoxic-chemotherapy">TREATMENT: Cytotoxic Chemotherapy</a><ul><li><a href="#a-62-year-old-man">A 62-year-old man</a></li><li><a href="#the-swog-0809-study-provided-data-to-support-the-efficacy-of-chemoradiation-and-sequential-chemotherapy">The SWOG 0809 study provided data to support the efficacy of chemoradiation and sequential chemotherapy</a></li><li><a href="#capecitabine-compared-with-observation-in-resected-biliary-tract-cancer-bilcap-a-randomised-controlled-multicentre-phase-3-study">Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study</a></li><li><a href="#adjuvant-s-1-jcog1202-ascot">Adjuvant S-1, JCOG1202, ASCOT</a></li><li><a href="#frontline-treatment-of-advanced-btc-abc-02">Frontline Treatment of Advanced BTC: ABC-02</a></li><li><a href="#tc1308">TC1308</a></li><li><a href="#folfox-in-btc-abc-06">FOLFOX in BTC (ABC-06)</a></li></ul></li><li><a href="#treatment-immunotherapy">TREATMENT: Immunotherapy</a><ul><li><a href="#a-64-year-old-woman-with-metastatic-gallbladder-cancer">A 64-year-old woman with metastatic gallbladder cancer</a></li><li><a href="#topaz-1-durvalumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc">TOPAZ-1: Durvalumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</a></li><li><a href="#a-54-year-old-man">A 54-year-old man</a></li><li><a href="#keynote-966-pembrolizumab-and-gemcitabine--cisplatin-in-patients-with-advanced-btc">KEYNOTE-966: Pembrolizumab and Gemcitabine + Cisplatin in Patients With Advanced BTC</a></li><li><a href="#what-did-we-learn-from-topaz-1-and-keynote-966">What did we learn from TOPAZ-1 and KEYNOTE-966</a></li><li><a href="#gemcitabine-and-s-1-plus-nivolumab-in-advanced-biliary-tract-cancer-a-phase-ii-t1219-study">Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study</a></li></ul></li><li><a href="#treatment-target">TREATMENT: Target</a><ul><li><a href="#esmo-2024-1">ESMO 2024</a></li><li><a href="#a-72-year-old-man">A 72-year-old man</a></li><li><a href="#approved-fgfr-inhibitors-for-advanced-cholangiocarcinoma-key-phase-ii-trials">Approved FGFR Inhibitors for Advanced Cholangiocarcinoma: Key Phase II Trials</a></li><li><a href="#fgfr-inhibitors-unique-class-specific-adverse-events">FGFR Inhibitors: Unique Class-Specific Adverse Events</a></li><li><a href="#idh1-mutations-in-icc">IDH1 Mutations in ICC</a></li><li><a href="#claridhy-ivosidenib-vs-placebo-in-previously-treated-cholangiocarcinoma-with-idh1-mutation">ClarIDHy: Ivosidenib vs Placebo in Previously Treated Cholangiocarcinoma With IDH1 Mutation</a></li><li><a href="#a-75-year-old-feman">A 75-year-old feman</a></li><li><a href="#dabrafenib--trametinib-for-brafv600e%E2%80%93mutated-btc-tumor-size-change-and-response-duration">Dabrafenib + Trametinib for BRAFV600Eâ€“Mutated BTC: Tumor Size Change and Response Duration</a></li><li><a href="#a-74-year-old-man">A 74-year-old man</a></li><li><a href="#destiny-pantumor02-phase-ii-trial">DESTINY-PanTumor02 Phase II Trial</a></li><li><a href="#zanidatamab-zw25-a-humanized-igg1-like-biparatopic-antibody">Zanidatamab (ZW25): A Humanized IgG1-like Biparatopic Antibody</a></li><li><a href="#herizon-btc-01-zanidatamab-for-previously-treated-her2%E2%80%90amplified-biliary-tract-cancer">HERIZON-BTC-01: Zanidatamab for Previously Treated HER2â€Amplified Biliary Tract Cancer</a></li><li><a href="#incidence-of-therapeutic-targets-in-advanced-biliary-tract-cancers">Incidence of Therapeutic Targets in Advanced Biliary Tract Cancers</a></li></ul></li><li><a href="#takeaway">Takeaway</a><ul><li><a href="#precision-oncology-is-key-for-management-of-advanced-cholangiocarcinoma">Precision Oncology Is Key for Management of Advanced Cholangiocarcinoma</a></li><li><a href="#tldr">TL;DR</a></li><li><a href="#thank-you">Thank you</a></li><li><a href="#table-of-contents">Table of Contents</a></li></ul></li></ul></div><p></p>
<footer><a href="#table-of-contents">â– </a></footer>
</section>
<script>!function(){"use strict";const t={h1:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"1"},style:"display: block; font-size: 2em; margin-block-start: 0.67em; margin-block-end: 0.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h2:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"2"},style:"display: block; font-size: 1.5em; margin-block-start: 0.83em; margin-block-end: 0.83em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h3:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"3"},style:"display: block; font-size: 1.17em; margin-block-start: 1em; margin-block-end: 1em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h4:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"4"},style:"display: block; margin-block-start: 1.33em; margin-block-end: 1.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h5:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"5"},style:"display: block; font-size: 0.83em; margin-block-start: 1.67em; margin-block-end: 1.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h6:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"6"},style:"display: block; font-size: 0.67em; margin-block-start: 2.33em; margin-block-end: 2.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},span:{proto:()=>HTMLSpanElement},pre:{proto:()=>HTMLElement,style:"display: block; font-family: monospace; white-space: pre; margin: 1em 0; --marp-auto-scaling-white-space: pre;"}},e="data-marp-auto-scaling-wrapper",i="data-marp-auto-scaling-svg",n="data-marp-auto-scaling-container";class s extends HTMLElement{container;containerSize;containerObserver;svg;svgComputedStyle;svgPreserveAspectRatio="xMinYMid meet";wrapper;wrapperSize;wrapperObserver;constructor(){super();const t=t=>([e])=>{const{width:i,height:n}=e.contentRect;this[t]={width:i,height:n},this.updateSVGRect()};this.attachShadow({mode:"open"}),this.containerObserver=new ResizeObserver(t("containerSize")),this.wrapperObserver=new ResizeObserver(((...e)=>{t("wrapperSize")(...e),this.flushSvgDisplay()}))}static get observedAttributes(){return["data-downscale-only"]}connectedCallback(){this.shadowRoot.innerHTML=`\n<style>\n  svg[${i}] { display: block; width: 100%; height: auto; vertical-align: top; }\n  span[${n}] { display: table; white-space: var(--marp-auto-scaling-white-space, nowrap); width: max-content; }\n</style>\n<div ${e}>\n  <svg part="svg" ${i}>\n    <foreignObject><span ${n}><slot></slot></span></foreignObject>\n  </svg>\n</div>\n    `.split(/\n\s*/).join(""),this.wrapper=this.shadowRoot.querySelector(`div[${e}]`)??void 0;const t=this.svg;this.svg=this.wrapper?.querySelector(`svg[${i}]`)??void 0,this.svg!==t&&(this.svgComputedStyle=this.svg?window.getComputedStyle(this.svg):void 0),this.container=this.svg?.querySelector(`span[${n}]`)??void 0,this.observe()}disconnectedCallback(){this.svg=void 0,this.svgComputedStyle=void 0,this.wrapper=void 0,this.container=void 0,this.observe()}attributeChangedCallback(){this.observe()}flushSvgDisplay(){const{svg:t}=this;t&&(t.style.display="inline",requestAnimationFrame((()=>{t.style.display=""})))}observe(){this.containerObserver.disconnect(),this.wrapperObserver.disconnect(),this.wrapper&&this.wrapperObserver.observe(this.wrapper),this.container&&this.containerObserver.observe(this.container),this.svgComputedStyle&&this.observeSVGStyle(this.svgComputedStyle)}observeSVGStyle(t){const e=()=>{const i=(()=>{const e=t.getPropertyValue("--preserve-aspect-ratio");if(e)return e.trim();return`x${(({textAlign:t,direction:e})=>{if(t.endsWith("left"))return"Min";if(t.endsWith("right"))return"Max";if("start"===t||"end"===t){let i="rtl"===e;return"end"===t&&(i=!i),i?"Max":"Min"}return"Mid"})(t)}YMid meet`})();i!==this.svgPreserveAspectRatio&&(this.svgPreserveAspectRatio=i,this.updateSVGRect()),t===this.svgComputedStyle&&requestAnimationFrame(e)};e()}updateSVGRect(){let t=Math.ceil(this.containerSize?.width??0);const e=Math.ceil(this.containerSize?.height??0);void 0!==this.dataset.downscaleOnly&&(t=Math.max(t,this.wrapperSize?.width??0));const i=this.svg?.querySelector(":scope > foreignObject");if(i?.setAttribute("width",`${t}`),i?.setAttribute("height",`${e}`),this.svg&&(this.svg.setAttribute("viewBox",`0 0 ${t} ${e}`),this.svg.setAttribute("preserveAspectRatio",this.svgPreserveAspectRatio),this.svg.style.height=t<=0||e<=0?"0":""),this.container){const t=this.svgPreserveAspectRatio.toLowerCase();this.container.style.marginLeft=t.startsWith("xmid")||t.startsWith("xmax")?"auto":"0",this.container.style.marginRight=t.startsWith("xmi")?"auto":"0"}}}const r=(t,{attrs:e={},style:i})=>class extends t{constructor(...t){super(...t);for(const[t,i]of Object.entries(e))this.hasAttribute(t)||this.setAttribute(t,i);this._shadow()}static get observedAttributes(){return["data-auto-scaling"]}connectedCallback(){this._update()}attributeChangedCallback(){this._update()}_shadow(){if(!this.shadowRoot)try{this.attachShadow({mode:"open"})}catch(t){if(!(t instanceof Error&&"NotSupportedError"===t.name))throw t}return this.shadowRoot}_update(){const t=this._shadow();if(t){const e=i?`<style>:host { ${i} }</style>`:"";let n="<slot></slot>";const{autoScaling:s}=this.dataset;if(void 0!==s){n=`<marp-auto-scaling exportparts="svg:auto-scaling" ${"downscale-only"===s?"data-downscale-only":""}>${n}</marp-auto-scaling>`}t.innerHTML=e+n}}};let o;const a=Symbol();let l;const c="marpitSVGPolyfill:setZoomFactor,",d=Symbol(),h=Symbol();const g=()=>{const t="Apple Computer, Inc."===navigator.vendor,e=t?[u]:[],i={then:e=>(t?(async()=>{if(void 0===l){const t=document.createElement("canvas");t.width=10,t.height=10;const e=t.getContext("2d"),i=new Image(10,10),n=new Promise((t=>{i.addEventListener("load",(()=>t()))}));i.crossOrigin="anonymous",i.src="data:image/svg+xml;charset=utf8,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20width%3D%2210%22%20height%3D%2210%22%20viewBox%3D%220%200%201%201%22%3E%3CforeignObject%20width%3D%221%22%20height%3D%221%22%20requiredExtensions%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%3E%3Cdiv%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%20style%3D%22width%3A%201px%3B%20height%3A%201px%3B%20background%3A%20red%3B%20position%3A%20relative%22%3E%3C%2Fdiv%3E%3C%2FforeignObject%3E%3C%2Fsvg%3E",await n,e.drawImage(i,0,0),l=e.getImageData(5,5,1,1).data[3]<128}return l})().then((t=>{null==e||e(t?[u]:[])})):null==e||e([]),i)};return Object.assign(e,i)};let p,m;function u(t){const e="object"==typeof t&&t.target||document,i="object"==typeof t?t.zoom:t;window[h]||(Object.defineProperty(window,h,{configurable:!0,value:!0}),document.body.style.zoom=1.0001,document.body.offsetHeight,document.body.style.zoom=1,window.addEventListener("message",(({data:t,origin:e})=>{if(e===window.origin)try{if(t&&"string"==typeof t&&t.startsWith(c)){const[,e]=t.split(","),i=Number.parseFloat(e);Number.isNaN(i)||(m=i)}}catch(t){console.error(t)}})));let n=!1;Array.from(e.querySelectorAll("svg[data-marpit-svg]"),(t=>{var e,s,r,o;t.style.transform||(t.style.transform="translateZ(0)");const a=i||m||t.currentScale||1;p!==a&&(p=a,n=a);const l=t.getBoundingClientRect(),{length:c}=t.children;for(let i=0;i<c;i+=1){const n=t.children[i];if(n.getScreenCTM){const t=n.getScreenCTM();if(t){const i=null!==(s=null===(e=n.x)||void 0===e?void 0:e.baseVal.value)&&void 0!==s?s:0,c=null!==(o=null===(r=n.y)||void 0===r?void 0:r.baseVal.value)&&void 0!==o?o:0,d=n.children.length;for(let e=0;e<d;e+=1){const s=n.children[e];if("SECTION"===s.tagName){const{style:e}=s;e.transformOrigin||(e.transformOrigin=`${-i}px ${-c}px`),e.transform=`scale(${a}) matrix(${t.a}, ${t.b}, ${t.c}, ${t.d}, ${t.e-l.left}, ${t.f-l.top}) translateZ(0.0001px)`;break}}}}}})),!1!==n&&Array.from(e.querySelectorAll("iframe"),(({contentWindow:t})=>{null==t||t.postMessage(`${c}${n}`,"null"===window.origin?"*":window.origin)}))}function v({once:t=!1,target:e=document}={}){const i=function(t=document){if(t[d])return t[d];let e=!0;const i=()=>{e=!1,delete t[d]};Object.defineProperty(t,d,{configurable:!0,value:i});let n=[],s=!1;(async()=>{try{n=await g()}finally{s=!0}})();const r=()=>{for(const e of n)e({target:t});s&&0===n.length||e&&window.requestAnimationFrame(r)};return r(),i}(e);return t?(i(),()=>{}):i}p=1,m=void 0;const w=Symbol(),b=(e=document)=>{if("undefined"==typeof window)throw new Error("Marp Core's browser script is valid only in browser context.");if(((e=document)=>{const i=window[a];i||customElements.define("marp-auto-scaling",s);for(const n of Object.keys(t)){const s=`marp-${n}`,a=t[n].proto();(o??(o=!!document.createElement("div",{is:"marp-auto-scaling"}).outerHTML.startsWith("<div is"),o))&&a!==HTMLElement?i||customElements.define(s,r(a,{style:t[n].style}),{extends:n}):(i||customElements.define(s,r(HTMLElement,t[n])),e.querySelectorAll(`${n}[is="${s}"]`).forEach((t=>{t.outerHTML=t.outerHTML.replace(new RegExp(`^<${n}`,"i"),`<${s}`).replace(new RegExp(`</${n}>$`,"i"),`</${s}>`)})))}window[a]=!0})(e),e[w])return e[w];const i=v({target:e}),n=()=>{i(),delete e[w]},l=Object.assign(n,{cleanup:n,update:()=>b(e)});return Object.defineProperty(e,w,{configurable:!0,value:l}),l},y=document.currentScript;b(y?y.getRootNode():document)}();
</script></foreignObject></svg></div></body></html><div class="bespoke-marp-note" data-index="0" tabindex="0"><p>![RLQ h:50](https://i.imgur.com/3fIm24v.png)</p></div><div class="bespoke-marp-note" data-index="32" tabindex="0"><p>A phase III trial (ABC-02) randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter), each administered on days 1 and 8, every 3 weeks for eight cycles, or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks. The primary end point was overall survival.</p><p>The median overall survival was 11.7 months among the 204 patients in the cisplatinâ€“gemcitabine group and 8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; P&lt;0.001).</p><p>The median progression-free survival was 8.0 months in the cisplatinâ€“gemcitabine group and 5.0 months in the gemcitabine-only group (P&lt;0.001). In addition, the rate of tumor control among patients in the cisplatinâ€“gemcitabine group was significantly increased (81.4% vs. 71.8%, P=0.049).</p></div><div class="bespoke-marp-note" data-index="40" tabindex="0"><p>å–®ç´”ä»¥ä¸­ä½æ•¸å­˜æ´»ä¾†çœ‹ï¼Œåªæœ‰æ”¹å–„ç´„ä¸€å€‹æœˆå·¦å³çš„æ™‚é–“ï¼Œæ•ˆæžœä¼¼ä¹Žä¸æ˜¯éžå¸¸å¥½ï¼Œä½†æ˜¯å¾žå­˜æ´»æ›²ç·šä¾†çœ‹ï¼Œå¯ä»¥ç™¼ç¾å…©å¹´å­˜æ´»çŽ‡ 24.9% vs. 10.4%ï¼Œç›¸å·®è¶…éŽå…©å€ï¼Œä»¥ç™½è©±ä¾†èªªï¼Œï¼‚å‚³çµ±åŒ–å­¸æ²»ç™‚å…©å¹´å­˜æ´»çŽ‡åªæœ‰ä¸€æˆï¼Œä½†æ˜¯ä½¿ç”¨å…ç–«æ²»ç™‚æœ‰å››åˆ†ä¹‹ä¸€çš„æ©Ÿæœƒæ´»è¶…éŽå…©å¹´ï¼‚ï¼Œé€™äº›é•·æœŸå­˜æ´»çš„å€‹æ¡ˆï¼Œåœ¨æœªä¾†è¿½è¹¤æ›´ä¹…çš„è³‡æ–™å¯ä»¥å‘Šè¨´æˆ‘å€‘é€™äº›ç—…æ‚£æ˜¯å¦èƒ½å¤ é•·æœŸå­˜æ´»é”åˆ°æ²»ç™’çš„æ©Ÿæœƒã€‚</p></div><div class="bespoke-marp-note" data-index="52" tabindex="0"><p>The most common adverse reactions occurring in 20% or more of patients were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, abdominal pain, dry skin, arthralgia, dysgeusia, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting.</p></div><div class="bespoke-marp-note" data-index="70" tabindex="0"><p>![bg right:50% h:250px](https://i.imgur.com/ZxXHT4V.png)</p></div><script>/*!! License: https://unpkg.com/@marp-team/marp-cli@4.0.3/lib/bespoke.js.LICENSE.txt */
!function(){"use strict";function e(e){return e&&e.__esModule&&Object.prototype.hasOwnProperty.call(e,"default")?e.default:e}var t,n,r=(n||(n=1,t={from:function(e,t){var n,r=1===(e.parent||e).nodeType?e.parent||e:document.querySelector(e.parent||e),o=[].filter.call("string"==typeof e.slides?r.querySelectorAll(e.slides):e.slides||r.children,(function(e){return"SCRIPT"!==e.nodeName})),a={},i=function(e,t){return(t=t||{}).index=o.indexOf(e),t.slide=e,t},s=function(e,t){a[e]=(a[e]||[]).filter((function(e){return e!==t}))},c=function(e,t){return(a[e]||[]).reduce((function(e,n){return e&&!1!==n(t)}),!0)},l=function(e,t){o[e]&&(n&&c("deactivate",i(n,t)),n=o[e],c("activate",i(n,t)))},d=function(e,t){var r=o.indexOf(n)+e;c(e>0?"next":"prev",i(n,t))&&l(r,t)},u={off:s,on:function(e,t){return(a[e]||(a[e]=[])).push(t),s.bind(null,e,t)},fire:c,slide:function(e,t){if(!arguments.length)return o.indexOf(n);c("slide",i(o[e],t))&&l(e,t)},next:d.bind(null,1),prev:d.bind(null,-1),parent:r,slides:o,destroy:function(e){c("destroy",i(n,e)),a={}}};return(t||[]).forEach((function(e){e(u)})),n||l(0),u}}),t),o=e(r);const a=document.body,i=(...e)=>history.replaceState(...e),s="",c="presenter",l="next",d=["",c,l],u="bespoke-marp-",f=`data-${u}`,m=(e,{protocol:t,host:n,pathname:r,hash:o}=location)=>{const a=e.toString();return`${t}//${n}${r}${a?"?":""}${a}${o}`},g=()=>a.dataset.bespokeView,p=e=>new URLSearchParams(location.search).get(e),v=(e,t={})=>{const n={location,setter:i,...t},r=new URLSearchParams(n.location.search);for(const t of Object.keys(e)){const n=e[t];"string"==typeof n?r.set(t,n):r.delete(t)}try{n.setter({...window.history.state??{}},"",m(r,n.location))}catch(e){console.error(e)}},h=(()=>{const e="bespoke-marp";try{return localStorage.setItem(e,e),localStorage.removeItem(e),!0}catch{return!1}})(),y=e=>{try{return localStorage.getItem(e)}catch{return null}},b=(e,t)=>{try{return localStorage.setItem(e,t),!0}catch{return!1}},w=e=>{try{return localStorage.removeItem(e),!0}catch{return!1}},x=(e,t)=>{const n="aria-hidden";t?e.setAttribute(n,"true"):e.removeAttribute(n)},k=e=>{e.parent.classList.add(`${u}parent`),e.slides.forEach((e=>e.classList.add(`${u}slide`))),e.on("activate",(t=>{const n=`${u}active`,r=t.slide,o=r.classList,a=!o.contains(n);if(e.slides.forEach((e=>{e.classList.remove(n),x(e,!0)})),o.add(n),x(r,!1),a){const e=`${n}-ready`;o.add(e),document.body.clientHeight,o.remove(e)}}))},$=e=>{let t=0,n=0;Object.defineProperty(e,"fragments",{enumerable:!0,value:e.slides.map((e=>[null,...e.querySelectorAll("[data-marpit-fragment]")]))});const r=r=>void 0!==e.fragments[t][n+r],o=(r,o)=>{t=r,n=o,e.fragments.forEach(((e,t)=>{e.forEach(((e,n)=>{if(null==e)return;const a=t<r||t===r&&n<=o;e.setAttribute(`${f}fragment`,(a?"":"in")+"active");const i=`${f}current-fragment`;t===r&&n===o?e.setAttribute(i,"current"):e.removeAttribute(i)}))})),e.fragmentIndex=o;const a={slide:e.slides[r],index:r,fragments:e.fragments[r],fragmentIndex:o};e.fire("fragment",a)};e.on("next",(({fragment:a=!0})=>{if(a){if(r(1))return o(t,n+1),!1;const a=t+1;e.fragments[a]&&o(a,0)}else{const r=e.fragments[t].length;if(n+1<r)return o(t,r-1),!1;const a=e.fragments[t+1];a&&o(t+1,a.length-1)}})),e.on("prev",(({fragment:a=!0})=>{if(r(-1)&&a)return o(t,n-1),!1;const i=t-1;e.fragments[i]&&o(i,e.fragments[i].length-1)})),e.on("slide",(({index:t,fragment:n})=>{let r=0;if(void 0!==n){const o=e.fragments[t];if(o){const{length:e}=o;r=-1===n?e-1:Math.min(Math.max(n,0),e-1)}}o(t,r)})),o(0,0)},E=document,L=()=>!(!E.fullscreenEnabled&&!E.webkitFullscreenEnabled),S=()=>!(!E.fullscreenElement&&!E.webkitFullscreenElement),P=e=>{e.fullscreen=()=>{L()&&(async()=>{S()?(E.exitFullscreen||E.webkitExitFullscreen)?.call(E):((e=E.body)=>{(e.requestFullscreen||e.webkitRequestFullscreen)?.call(e)})()})()},document.addEventListener("keydown",(t=>{"f"!==t.key&&"F11"!==t.key||t.altKey||t.ctrlKey||t.metaKey||!L()||(e.fullscreen(),t.preventDefault())}))},_=`${u}inactive`,T=(e=2e3)=>({parent:t,fire:n})=>{const r=t.classList,o=e=>n(`marp-${e?"":"in"}active`);let a;const i=()=>{a&&clearTimeout(a),a=setTimeout((()=>{r.add(_),o()}),e),r.contains(_)&&(r.remove(_),o(!0))};for(const e of["mousedown","mousemove","touchend"])document.addEventListener(e,i);setTimeout(i,0)},I=["AUDIO","BUTTON","INPUT","SELECT","TEXTAREA","VIDEO"],M=e=>{e.parent.addEventListener("keydown",(e=>{if(!e.target)return;const t=e.target;(I.includes(t.nodeName)||"true"===t.contentEditable)&&e.stopPropagation()}))},O=e=>{window.addEventListener("load",(()=>{for(const t of e.slides){const e=t.querySelector("marp-auto-scaling, [data-auto-scaling], [data-marp-fitting]");t.setAttribute(`${f}load`,e?"":"hideable")}}))},A=({interval:e=250}={})=>t=>{document.addEventListener("keydown",(e=>{if(" "===e.key&&e.shiftKey)t.prev();else if("ArrowLeft"===e.key||"ArrowUp"===e.key||"PageUp"===e.key)t.prev({fragment:!e.shiftKey});else if(" "!==e.key||e.shiftKey)if("ArrowRight"===e.key||"ArrowDown"===e.key||"PageDown"===e.key)t.next({fragment:!e.shiftKey});else if("End"===e.key)t.slide(t.slides.length-1,{fragment:-1});else{if("Home"!==e.key)return;t.slide(0)}else t.next();e.preventDefault()}));let n,r,o=0;t.parent.addEventListener("wheel",(a=>{let i=!1;const s=(e,t)=>{e&&(i=i||((e,t)=>((e,t)=>{const n="X"===t?"Width":"Height";return e[`client${n}`]<e[`scroll${n}`]})(e,t)&&((e,t)=>{const{overflow:n}=e,r=e[`overflow${t}`];return"auto"===n||"scroll"===n||"auto"===r||"scroll"===r})(getComputedStyle(e),t))(e,t)),e?.parentElement&&s(e.parentElement,t)};if(0!==a.deltaX&&s(a.target,"X"),0!==a.deltaY&&s(a.target,"Y"),i)return;a.preventDefault();const c=Math.sqrt(a.deltaX**2+a.deltaY**2);if(void 0!==a.wheelDelta){if(void 0===a.webkitForce&&Math.abs(a.wheelDelta)<40)return;if(a.deltaMode===a.DOM_DELTA_PIXEL&&c<4)return}else if(a.deltaMode===a.DOM_DELTA_PIXEL&&c<12)return;r&&clearTimeout(r),r=setTimeout((()=>{n=0}),e);const l=Date.now()-o<e,d=c<=n;if(n=c,l||d)return;let u;(a.deltaX>0||a.deltaY>0)&&(u="next"),(a.deltaX<0||a.deltaY<0)&&(u="prev"),u&&(t[u](),o=Date.now())}))},C=(e=`.${u}osc`)=>{const t=document.querySelector(e);if(!t)return()=>{};const n=(e,n)=>{t.querySelectorAll(`[${f}osc=${JSON.stringify(e)}]`).forEach(n)};return L()||n("fullscreen",(e=>e.style.display="none")),h||n("presenter",(e=>{e.disabled=!0,e.title="Presenter view is disabled due to restricted localStorage."})),e=>{t.addEventListener("click",(t=>{if(t.target instanceof HTMLElement){const{bespokeMarpOsc:n}=t.target.dataset;n&&t.target.blur();const r={fragment:!t.shiftKey};"next"===n?e.next(r):"prev"===n?e.prev(r):"fullscreen"===n?e?.fullscreen():"presenter"===n&&e.openPresenterView()}})),e.parent.appendChild(t),e.on("activate",(({index:t})=>{n("page",(n=>n.textContent=`Page ${t+1} of ${e.slides.length}`))})),e.on("fragment",(({index:t,fragments:r,fragmentIndex:o})=>{n("prev",(e=>e.disabled=0===t&&0===o)),n("next",(n=>n.disabled=t===e.slides.length-1&&o===r.length-1))})),e.on("marp-active",(()=>x(t,!1))),e.on("marp-inactive",(()=>x(t,!0))),L()&&(e=>{for(const t of["","webkit"])E.addEventListener(t+"fullscreenchange",e)})((()=>n("fullscreen",(e=>e.classList.toggle("exit",L()&&S())))))}},D=e=>{window.addEventListener("message",(t=>{if(t.origin!==window.origin)return;const[n,r]=t.data.split(":");if("navigate"===n){const[t,n]=r.split(",");let o=Number.parseInt(t,10),a=Number.parseInt(n,10)+1;a>=e.fragments[o].length&&(o+=1,a=0),e.slide(o,{fragment:a})}}))};var N,B,q,K,j,F,V,U={exports:{}},X=(N||(N=1,U.exports=(B=["area","base","br","col","command","embed","hr","img","input","keygen","link","meta","param","source","track","wbr"],q=function(e){return String(e).replace(/[&<>"']/g,(function(e){return"&"+K[e]+";"}))},K={"&":"amp","<":"lt",">":"gt",'"':"quot","'":"apos"},j="dangerouslySetInnerHTML",F={className:"class",htmlFor:"for"},V={},function(e,t){var n=[],r="";t=t||{};for(var o=arguments.length;o-- >2;)n.push(arguments[o]);if("function"==typeof e)return t.children=n.reverse(),e(t);if(e){if(r+="<"+e,t)for(var a in t)!1!==t[a]&&null!=t[a]&&a!==j&&(r+=" "+(F[a]?F[a]:q(a))+'="'+q(t[a])+'"');r+=">"}if(-1===B.indexOf(e)){if(t[j])r+=t[j].__html;else for(;n.length;){var i=n.pop();if(i)if(i.pop)for(var s=i.length;s--;)n.push(i[s]);else r+=!0===V[i]?i:q(i)}r+=e?"</"+e+">":""}return V[r]=!0,r})),U.exports),H=e(X);const R=({children:e})=>H(null,null,...e),W=`${u}presenter-`,J={container:`${W}container`,dragbar:`${W}dragbar-container`,next:`${W}next`,nextContainer:`${W}next-container`,noteContainer:`${W}note-container`,noteWrapper:`${W}note-wrapper`,noteButtons:`${W}note-buttons`,infoContainer:`${W}info-container`,infoPage:`${W}info-page`,infoPageText:`${W}info-page-text`,infoPagePrev:`${W}info-page-prev`,infoPageNext:`${W}info-page-next`,noteButtonsBigger:`${W}note-bigger`,noteButtonsSmaller:`${W}note-smaller`,infoTime:`${W}info-time`,infoTimer:`${W}info-timer`},Y=e=>{const{title:t}=document;document.title="[Presenter view]"+(t?` - ${t}`:"");const n={},r=e=>(n[e]=n[e]||document.querySelector(`.${e}`),n[e]);document.body.appendChild((e=>{const t=document.createElement("div");return t.className=J.container,t.appendChild(e),t.insertAdjacentHTML("beforeend",H(R,null,H("div",{class:J.nextContainer},H("iframe",{class:J.next,src:"?view=next"})),H("div",{class:J.dragbar}),H("div",{class:J.noteContainer},H("div",{class:J.noteWrapper}),H("div",{class:J.noteButtons},H("button",{class:J.noteButtonsSmaller,tabindex:"-1",title:"Smaller notes font size"},"Smaller notes font size"),H("button",{class:J.noteButtonsBigger,tabindex:"-1",title:"Bigger notes font size"},"Bigger notes font size"))),H("div",{class:J.infoContainer},H("div",{class:J.infoPage},H("button",{class:J.infoPagePrev,tabindex:"-1",title:"Previous"},"Previous"),H("span",{class:J.infoPageText}),H("button",{class:J.infoPageNext,tabindex:"-1",title:"Next"},"Next")),H("time",{class:J.infoTime,title:"Current time"}),H("time",{class:J.infoTimer,title:"Timer"})))),t})(e.parent)),(e=>{let t=!1;r(J.dragbar).addEventListener("mousedown",(()=>{t=!0,r(J.dragbar).classList.add("active")})),window.addEventListener("mouseup",(()=>{t=!1,r(J.dragbar).classList.remove("active")})),window.addEventListener("mousemove",(e=>{if(!t)return;const n=e.clientX/document.documentElement.clientWidth*100;r(J.container).style.setProperty("--bespoke-marp-presenter-split-ratio",`${Math.max(0,Math.min(100,n))}%`)})),r(J.nextContainer).addEventListener("click",(()=>e.next()));const n=r(J.next),o=(a=n,(e,t)=>a.contentWindow?.postMessage(`navigate:${e},${t}`,"null"===window.origin?"*":window.origin));var a;n.addEventListener("load",(()=>{r(J.nextContainer).classList.add("active"),o(e.slide(),e.fragmentIndex),e.on("fragment",(({index:e,fragmentIndex:t})=>o(e,t)))}));const i=document.querySelectorAll(".bespoke-marp-note");i.forEach((e=>{e.addEventListener("keydown",(e=>e.stopPropagation())),r(J.noteWrapper).appendChild(e)})),e.on("activate",(()=>i.forEach((t=>t.classList.toggle("active",t.dataset.index==e.slide())))));let s=0;const c=e=>{s=Math.max(-5,s+e),r(J.noteContainer).style.setProperty("--bespoke-marp-note-font-scale",(1.2**s).toFixed(4))},l=()=>c(1),d=()=>c(-1),u=r(J.noteButtonsBigger),f=r(J.noteButtonsSmaller);u.addEventListener("click",(()=>{u.blur(),l()})),f.addEventListener("click",(()=>{f.blur(),d()})),document.addEventListener("keydown",(e=>{"+"===e.key&&l(),"-"===e.key&&d()}),!0),e.on("activate",(({index:t})=>{r(J.infoPageText).textContent=`${t+1} / ${e.slides.length}`}));const m=r(J.infoPagePrev),g=r(J.infoPageNext);m.addEventListener("click",(t=>{m.blur(),e.prev({fragment:!t.shiftKey})})),g.addEventListener("click",(t=>{g.blur(),e.next({fragment:!t.shiftKey})})),e.on("fragment",(({index:t,fragments:n,fragmentIndex:r})=>{m.disabled=0===t&&0===r,g.disabled=t===e.slides.length-1&&r===n.length-1}));let p=new Date;const v=()=>{const e=new Date,t=e=>`${Math.floor(e)}`.padStart(2,"0"),n=e.getTime()-p.getTime(),o=t(n/1e3%60),a=t(n/1e3/60%60),i=t(n/36e5%24);r(J.infoTime).textContent=e.toLocaleTimeString(),r(J.infoTimer).textContent=`${i}:${a}:${o}`};v(),setInterval(v,250),r(J.infoTimer).addEventListener("click",(()=>{p=new Date}))})(e)},z=e=>{if(!(e=>e.syncKey&&"string"==typeof e.syncKey)(e))throw new Error("The current instance of Bespoke.js is invalid for Marp bespoke presenter plugin.");Object.defineProperties(e,{openPresenterView:{enumerable:!0,value:G},presenterUrl:{enumerable:!0,get:Q}}),h&&document.addEventListener("keydown",(t=>{"p"!==t.key||t.altKey||t.ctrlKey||t.metaKey||(t.preventDefault(),e.openPresenterView())}))};function G(){const{max:e,floor:t}=Math,n=e(t(.85*window.innerWidth),640),r=e(t(.85*window.innerHeight),360);return window.open(this.presenterUrl,W+this.syncKey,`width=${n},height=${r},menubar=no,toolbar=no`)}function Q(){const e=new URLSearchParams(location.search);return e.set("view","presenter"),e.set("sync",this.syncKey),m(e)}const Z=e=>{const t=g();return t===l&&e.appendChild(document.createElement("span")),{[s]:z,[c]:Y,[l]:D}[t]},ee=e=>{e.on("activate",(t=>{document.querySelectorAll(".bespoke-progress-parent > .bespoke-progress-bar").forEach((n=>{n.style.flexBasis=100*t.index/(e.slides.length-1)+"%"}))}))},te=e=>{const t=Number.parseInt(e,10);return Number.isNaN(t)?null:t},ne=(e={})=>{const t={history:!0,...e};return e=>{let n=!0;const r=e=>{const t=n;try{return n=!0,e()}finally{n=t}},o=(t={fragment:!0})=>{let n=t.fragment?te(p("f")||""):null;((t,n)=>{const{min:r,max:o}=Math,{fragments:a,slides:i}=e,s=o(0,r(t,i.length-1)),c=o(0,r(n||0,a[s].length-1));s===e.slide()&&c===e.fragmentIndex||e.slide(s,{fragment:c})})((()=>{if(location.hash){const[t]=location.hash.slice(1).split(":~:");if(/^\d+$/.test(t))return(te(t)??1)-1;const r=document.getElementById(t)||document.querySelector(`a[name="${CSS.escape(t)}"]`);if(r){const{length:t}=e.slides;for(let o=0;o<t;o+=1)if(e.slides[o].contains(r)){const t=e.fragments?.[o],a=r.closest("[data-marpit-fragment]");if(t&&a){const e=t.indexOf(a);e>=0&&(n=e)}return o}}}return 0})(),n)};e.on("fragment",(({index:e,fragmentIndex:r})=>{n||v({f:0===r||r.toString()},{location:{...location,hash:`#${e+1}`},setter:(...e)=>t.history?history.pushState(...e):history.replaceState(...e)})})),setTimeout((()=>{o(),window.addEventListener("hashchange",(()=>r((()=>{o({fragment:!1}),v({f:void 0})})))),window.addEventListener("popstate",(()=>{n||r((()=>o()))})),n=!1}),0)}},re=(e={})=>{const t=e.key||window.history.state?.marpBespokeSyncKey||Math.random().toString(36).slice(2),n=`bespoke-marp-sync-${t}`;var r;r={marpBespokeSyncKey:t},v({},{setter:(e,...t)=>i({...e,...r},...t)});const o=()=>{const e=y(n);return e?JSON.parse(e):Object.create(null)},a=e=>{const t=o(),r={...t,...e(t)};return b(n,JSON.stringify(r)),r},s=()=>{window.removeEventListener("pageshow",s),a((e=>({reference:(e.reference||0)+1})))};return e=>{s(),Object.defineProperty(e,"syncKey",{value:t,enumerable:!0});let r=!0;setTimeout((()=>{e.on("fragment",(e=>{r&&a((()=>({index:e.index,fragmentIndex:e.fragmentIndex})))}))}),0),window.addEventListener("storage",(t=>{if(t.key===n&&t.oldValue&&t.newValue){const n=JSON.parse(t.oldValue),o=JSON.parse(t.newValue);if(n.index!==o.index||n.fragmentIndex!==o.fragmentIndex)try{r=!1,e.slide(o.index,{fragment:o.fragmentIndex,forSync:!0})}finally{r=!0}}}));const i=()=>{const{reference:e}=o();void 0===e||e<=1?w(n):a((()=>({reference:e-1})))};window.addEventListener("pagehide",(e=>{e.persisted&&window.addEventListener("pageshow",s),i()})),e.on("destroy",i)}},{PI:oe,abs:ae,sqrt:ie,atan2:se}=Math,ce={passive:!0},le=({slope:e=-.7,swipeThreshold:t=30}={})=>n=>{let r;const o=n.parent,a=e=>{const t=o.getBoundingClientRect();return{x:e.pageX-(t.left+t.right)/2,y:e.pageY-(t.top+t.bottom)/2}};o.addEventListener("touchstart",(({touches:e})=>{r=1===e.length?a(e[0]):void 0}),ce),o.addEventListener("touchmove",(e=>{if(r)if(1===e.touches.length){e.preventDefault();const t=a(e.touches[0]),n=t.x-r.x,o=t.y-r.y;r.delta=ie(ae(n)**2+ae(o)**2),r.radian=se(n,o)}else r=void 0})),o.addEventListener("touchend",(o=>{if(r){if(r.delta&&r.delta>=t&&r.radian){const t=(r.radian-e+oe)%(2*oe)-oe;n[t<0?"next":"prev"](),o.stopPropagation()}r=void 0}}),ce)},de=new Map;de.clear(),de.set("none",{backward:{both:void 0,incoming:void 0,outgoing:void 0},forward:{both:void 0,incoming:void 0,outgoing:void 0}});const ue={both:"",outgoing:"outgoing-",incoming:"incoming-"},fe={forward:"",backward:"-backward"},me=e=>`--marp-bespoke-transition-animation-${e}`,ge=e=>`--marp-transition-${e}`,pe=me("name"),ve=me("duration"),he=e=>new Promise((t=>{const n={},r=document.createElement("div"),o=e=>{r.remove(),t(e)};r.addEventListener("animationstart",(()=>o(n))),Object.assign(r.style,{animationName:e,animationDuration:"1s",animationFillMode:"both",animationPlayState:"paused",position:"absolute",pointerEvents:"none"}),document.body.appendChild(r);const a=getComputedStyle(r).getPropertyValue(ge("duration"));a&&(n.defaultDuration=a),((e,t)=>{requestAnimationFrame((()=>{e.style.animationPlayState="running",requestAnimationFrame((()=>t(void 0)))}))})(r,o)})),ye=async e=>de.has(e)?de.get(e):(e=>{const t={},n=[];for(const[r,o]of Object.entries(ue))for(const[a,i]of Object.entries(fe)){const s=`marp-${o}transition${i}-${e}`;n.push(he(s).then((e=>{t[a]=t[a]||{},t[a][r]=e?{...e,name:s}:void 0})))}return Promise.all(n).then((()=>t))})(e).then((t=>(de.set(e,t),t))),be=e=>Object.values(e).flatMap(Object.values).every((e=>!e)),we=(e,{type:t,backward:n})=>{const r=e[n?"backward":"forward"],o=(()=>{const e=r[t],n=e=>({[pe]:e.name});if(e)return n(e);if(r.both){const e=n(r.both);return"incoming"===t&&(e[me("direction")]="reverse"),e}})();return!o&&n?we(e,{type:t,backward:!1}):o||{[pe]:"__bespoke_marp_transition_no_animation__"}},xe=e=>{if(e)try{const t=JSON.parse(e);if((e=>{if("object"!=typeof e)return!1;const t=e;return"string"==typeof t.name&&(void 0===t.duration||"string"==typeof t.duration)})(t))return t}catch{}},ke="_tSId",$e="_tA",Ee="bespoke-marp-transition-warming-up",Le=window.matchMedia("(prefers-reduced-motion: reduce)"),Se="__bespoke_marp_transition_reduced_outgoing__",Pe="__bespoke_marp_transition_reduced_incoming__",_e={forward:{both:void 0,incoming:{name:Pe},outgoing:{name:Se}},backward:{both:void 0,incoming:{name:Pe},outgoing:{name:Se}}},Te=e=>{if(!document.startViewTransition)return;const t=t=>(void 0!==t&&(e._tD=t),e._tD);let n;t(!1),((...e)=>{const t=[...new Set(e).values()];return Promise.all(t.map((e=>ye(e)))).then()})(...Array.from(document.querySelectorAll("section[data-transition], section[data-transition-back]")).flatMap((e=>[e.dataset.transition,e.dataset.transitionBack].flatMap((e=>{const t=xe(e);return[t?.name,t?.builtinFallback?`__builtin__${t.name}`:void 0]})).filter((e=>!!e))))).then((()=>{document.querySelectorAll("style").forEach((e=>{e.innerHTML=e.innerHTML.replace(/--marp-transition-duration:[^;}]*[;}]/g,(e=>e.slice(0,-1)+"!important"+e.slice(-1)))}))}));const r=(n,{back:r,cond:o})=>a=>{const i=t();if(i)return!!a[$e]||!("object"!=typeof i||(i.skipTransition(),!a.forSync));if(!o(a))return!0;const s=e.slides[e.slide()],c=()=>a.back??r,l="data-transition"+(c()?"-back":""),d=s.querySelector(`section[${l}]`);if(!d)return!0;const u=xe(d.getAttribute(l)??void 0);return!u||((async(e,{builtinFallback:t=!0}={})=>{let n=await ye(e);if(be(n)){if(!t)return;return n=await ye(`__builtin__${e}`),be(n)?void 0:n}return n})(u.name,{builtinFallback:u.builtinFallback}).then((e=>{if(!e){t(!0);try{n(a)}finally{t(!1)}return}let r=e;Le.matches&&(console.warn("Use a constant animation to transition because preferring reduced motion by viewer has detected."),r=_e);const o=document.getElementById(ke);o&&o.remove();const i=document.createElement("style");i.id=ke,document.head.appendChild(i),((e,t)=>{const n=[`:root{${ge("direction")}:${t.backward?-1:1};}`,":root:has(.bespoke-marp-inactive){cursor:none;}"],r=t=>{const n=e[t].both?.defaultDuration||e[t].outgoing?.defaultDuration||e[t].incoming?.defaultDuration;return"forward"===t?n:n||r("forward")},o=t.duration||r(t.backward?"backward":"forward");void 0!==o&&n.push(`::view-transition-group(*){${ve}:${o};}`);const a=e=>Object.entries(e).map((([e,t])=>`${e}:${t};`)).join("");return n.push(`::view-transition-old(root){${a(we(e,{...t,type:"outgoing"}))}}`,`::view-transition-new(root){${a(we(e,{...t,type:"incoming"}))}}`),n})(r,{backward:c(),duration:u.duration}).forEach((e=>i.sheet?.insertRule(e)));const s=document.documentElement.classList;s.add(Ee);let l=!1;const d=()=>{l||(n(a),l=!0,s.remove(Ee))},f=()=>{t(!1),i.remove(),s.remove(Ee)};try{t(!0);const e=document.startViewTransition(d);t(e),e.finished.finally(f)}catch(e){console.error(e),d(),f()}})),!1)};e.on("prev",r((t=>e.prev({...t,[$e]:!0})),{back:!0,cond:e=>e.index>0&&!((e.fragment??1)&&n.fragmentIndex>0)})),e.on("next",r((t=>e.next({...t,[$e]:!0})),{cond:t=>t.index+1<e.slides.length&&!(n.fragmentIndex+1<n.fragments.length)})),setTimeout((()=>{e.on("slide",r((t=>e.slide(t.index,{...t,[$e]:!0})),{cond:t=>{const n=e.slide();return t.index!==n&&(t.back=t.index<n,!0)}}))}),0),e.on("fragment",(e=>{n=e}))};let Ie;const Me=()=>(void 0===Ie&&(Ie="wakeLock"in navigator&&navigator.wakeLock),Ie),Oe=async()=>{const e=Me();if(e)try{return await e.request("screen")}catch(e){console.warn(e)}return null},Ae=async()=>{if(!Me())return;let e;const t=()=>{e&&"visible"===document.visibilityState&&Oe()};for(const e of["visibilitychange","fullscreenchange"])document.addEventListener(e,t);return e=await Oe(),e};((e=document.getElementById(":$p"))=>{(()=>{const e=p("view");a.dataset.bespokeView=e===l||e===c?e:""})();const t=(e=>{const t=p(e);return v({[e]:void 0}),t})("sync")||void 0;o.from(e,((...e)=>{const t=d.findIndex((e=>g()===e));return e.map((([e,n])=>e[t]&&n)).filter((e=>e))})([[1,1,0],re({key:t})],[[1,1,1],Z(e)],[[1,1,0],M],[[1,1,1],k],[[1,0,0],T()],[[1,1,1],O],[[1,1,1],ne({history:!1})],[[1,1,0],A()],[[1,1,0],P],[[1,0,0],ee],[[1,1,0],le()],[[1,0,0],C()],[[1,0,0],Te],[[1,1,1],$],[[1,1,0],Ae]))})()}();</script></body></html>